Optical Metabolic Imaging to Characterize Early Treatment Response in Head and Neck Cancer by Shah, Amy Trushar
  
Optical Metabolic Imaging to Characterize Early Treatment Response in Head and Neck Cancer 
 
By 
Amy Trushar Shah 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
 
DOCTOR OF PHILOSOPHY 
in 
Biomedical Engineering 
 
August, 2016 
Nashville, Tennessee 
 
Approved: 
Melissa C. Skala, Ph.D. 
H. Charles Manning, Ph.D. 
Rebecca S. Cook, Ph.D. 
Rick R. Haselton, Ph.D. 
Jill Gilbert, M.D. 
 
ii 
 
 
 
 
 
 
 
 
 
To my family.  
iii 
 
ACKNOWLEDGEMENTS 
 First, I would like to thank my advisor, Dr. Melissa Skala, for all her scientific and 
professional guidance throughout this dissertation work. I would also like to thank my committee 
members Dr. Charles Manning, Dr. Rebecca Cook, Dr. Rick Haselton, and Dr. Jill Gilbert for 
their complementary perspectives and insights toward this project. Additionally, I would like to 
thank all my collaborators, including Dr. Paula Pohlmann, Dr. Michelle Demory Beckler, Dr. 
Jonathan Irish, Kirsten Diggins, and Dr. Jim Higginbotham, for their valuable suggestions and 
for teaching me beneficial skillsets that were instrumental for these studies. Will Jones, as a high 
school student, and Taylor Cannon, as an undergraduate student, contributed toward cell culture 
assays and experiments. This work has used Vanderbilt core facilities, including the 
Translational Pathology Shared Resource, Cell Imaging Shared Resource, and Flow Cytometry 
Shared Resource. Additionally, the Cooperative Human Tissue Network was used for tissue 
collection. Funding sources for this work include the National Science Foundation (NSF) 
Graduate Research Fellowship. I would also like to thank all the graduate students in the 
Biophotonics Lab and Vanderbilt Biomedical Engineering department for their comradery. 
Finally, I would like to thank my parents and brother for their encouragement during this 
journey.   
iv 
 
TABLE OF CONTENTS 
Page 
 
DEDICATION ................................................................................................................................ ii 
 
ACKNOWLEDGEMENTS ........................................................................................................... iii 
 
LIST OF TABLES ......................................................................................................................... vi 
 
LIST OF FIGURES ...................................................................................................................... vii 
 
Chapter 
 
1. INTRODUCTION .....................................................................................................................1 
 
1.1 Motivation ......................................................................................................................1 
1.2 Specific Aims .................................................................................................................2 
1.3 Dissertation Outline .......................................................................................................4 
 
2. BACKGROUND .......................................................................................................................6 
 
2.1 Anatomy and Physiology of the Head and Neck ...........................................................6 
2.2 Prevalence and Diagnosis of Head and Neck Squamous Cell Carcinoma ....................7 
2.3 Treatment Methods for Head and Neck Cancer ............................................................8 
2.4 Optical Techniques for Head and Neck Cancer ...........................................................10 
2.5 Two-Photon Fluorescence Microscopy and Fluorescence Lifetime Imaging .............12 
2.6 Cellular Metabolism and Tumor Heterogeneity ..........................................................14 
 
3. OPTICAL METABOLIC IMAGING OF TREATMENT RESPONSE IN HUMAN  
      HEAD AND NECK CANCER SQUAMOUS CELL CARCINOMA ....................................17 
 
3.1 Abstract ........................................................................................................................17 
3.2 Introduction ..................................................................................................................18 
3.3 Materials and Methods .................................................................................................21 
3.4 Results ..........................................................................................................................26 
3.5 Discussion ....................................................................................................................35 
3.6 Acknowledgements ......................................................................................................38 
 
4. IN VIVO AUTOFLUORESCENCE IMAGING OF TUMOR HETEROGENEITY  
      IN RESPONSE TO TREATMENT .........................................................................................39 
 
4.1 Abstract ........................................................................................................................39 
4.2 Introduction ..................................................................................................................40 
4.3 Materials and Methods .................................................................................................43 
4.4 Results ..........................................................................................................................47 
v 
 
4.5 Discussion ....................................................................................................................58 
4.6 Acknowledgements ......................................................................................................62 
 
5. EX VIVO LABEL-FREE MICROSCOPY OF HEAD AND NECK CANCER  
      PATIENT TISSUES ................................................................................................................63 
 
5.1 Abstract ........................................................................................................................63 
5.2 Introduction ..................................................................................................................63 
5.3 Methods........................................................................................................................65 
5.4 Results ..........................................................................................................................66 
5.5 Discussion ....................................................................................................................70 
5.6 Acknowledgements ......................................................................................................71 
 
6. METABOLIC IMAGING OF HEAD AND NECK CANCER ORGANOIDS ......................72 
 
6.1 Abstract ........................................................................................................................72 
6.2 Introduction ..................................................................................................................73 
6.3 Materials and Methods .................................................................................................75 
6.4 Results ..........................................................................................................................78 
6.5 Discussion ....................................................................................................................91 
6.6 Acknowledgements ......................................................................................................95 
 
7. CONCLUSIONS AND FUTURE DIRECTIONS...................................................................96 
 
7.1 Summary and Conclusions ..........................................................................................96 
7.2 Future Directions .........................................................................................................99 
7.3 Contribution to the Field and Broader Impact ...........................................................102 
 
Appendix 
 
A. SUPPLEMENTARY MATERIAL FOR CHAPTER 4 .........................................................105 
 
B. SUPPLEMENTARY MATERIAL FOR CHAPTER 6 .........................................................109 
 
C. AUTOFLUORESCENCE FLOW SORTING OF BREAST CANCER CELL  
METABOLISM .....................................................................................................................112 
 
C.1 Abstract .....................................................................................................................112 
C.2 Introduction ...............................................................................................................112 
C.3 Methods .....................................................................................................................116 
C.4 Results .......................................................................................................................118 
C.5 Discussion .................................................................................................................128 
C.6 Acknowledgements ...................................................................................................132 
 
REFERENCES ............................................................................................................................133 
vi 
 
LIST OF TABLES 
Table                Page 
 
3.1 The short and long fluorescence lifetime components (τ1 and τ2, respectively), mean  
lifetime (τm), and contribution of the short lifetime component (α1) of NADH and  
FAD in SCC25 (a) and SCC61 (b) after treatment with cetuximab, BGT226, or  
cisplatin, as well as in OKF6 (c) ..............................................................................................34 
 
4.1 Validation of the heterogeneity index ......................................................................................55 
  
vii 
 
LIST OF FIGURES 
Figure                 Page  
 
2.1 Anatomy of the head and neck region .......................................................................................6 
2.2 EGFR signaling pathway ...........................................................................................................9 
2.3 Absorption and fluorescence emission energy diagram ..........................................................13 
2.4 Comparison between single-photon and two-photon excitation ..............................................13 
2.5 Fluorescence lifetime decay curve ...........................................................................................14 
2.6 The role of NADH and FAD in cellular metabolism ...............................................................15 
 
3.1 Cyanide treatment alters redox ratio, NADH α1, and FAD α1 in nonmalignant  
oral cells (OKF6) .....................................................................................................................26 
3.2 Optical metabolic endpoints distinguish malignant from nonmalignant cells .........................27 
3.3 Western blotting analysis verifies molecular targeting of cetuximab and BGT226 ................28 
3.4 Representative autofluorescence images after treatment .........................................................30 
3.5 Metabolic endpoints measure response in SCC25 and SCC61 after treatment .......................32 
 
4.1 In vivo validation of treatment effects .....................................................................................48 
4.2 In vivo images of FaDu xenografts 2 days after treatment with cetuximab or cisplatin ..........50 
4.3 The optical redox ratio, NAD(P)H fluorescence lifetime, and FAD fluorescence  
lifetime quantified from in vivo NAD(P)H and FAD autofluorescence images  
2 days after treatment ...............................................................................................................51 
4.4 In vivo heterogeneity analysis after treatment .........................................................................53 
4.5 Single-cell analysis using the dimensionality-reduction technique viSNE  
reduces seven optical metabolic imaging parameters to two dimensions for visualization  
of heterogeneity across individual cells ...................................................................................57 
 
5.1 Representative hematoxylin and eosin (H&E) histology stain (60x60µm image  
size), redox ratio, NADH lifetime, and FAD lifetime images (170x170µm image size)  
from malignant tongue .............................................................................................................67 
5.2 Representative images from squamous cell carcinoma of the tongue (top row)  
and normal tissue (bottom row) from the same patient ...........................................................68 
5.3 Representative images from adenocarcinoma (top row) and squamous cell  
carcinoma (bottom row) from the parotid salivary gland ........................................................69 
5.4 Representative images from patient tissue of laryngeal cancer ...............................................69 
 
6.1 Representative immunohistochemistry, histology, and autofluorescence images  
of tumor tissue and brightfield microscopy for organoid generation ......................................80 
6.2 Untreated organoids and in vivo tumor tissue display distinct optical metabolic  
imaging properties ...................................................................................................................82 
6.3 Untreated organoids contain cells with high levels of NAD(P)H intensity and  
cells with low levels of NAD(P)H intensity ............................................................................83 
6.4 Cell proliferation and cell death were quantified using Ki-67 and Cleaved  
Caspase 3, respectively, in FaDu xenografts after mice were treated for 2 days  
or 2 weeks, and tumor growth curves show treatment effects over 2 weeks in mice  
viii 
 
with FaDu xenografts ...............................................................................................................85 
6.5 Autofluorescence images show the redox ratio and fluorescence lifetimes  
of NAD(P)H and FAD in head and neck cancer organoids treated for 1 day with  
cetuximab, cisplatin, or their combination ...............................................................................87 
6.6 The redox ratio and fluorescence lifetimes of NAD(P)H and FAD were quantified  
in organoids treated for 1 day with cetuximab, cisplatin, or their combination ......................88 
6.7 Cellular heterogeneity was analyzed based on NAD(P)H fluorescence lifetime  
in head and neck cancer organoids after 1 day of treatment with cetuximab,  
cisplatin, and their combination ...............................................................................................90 
 
A.1 The short fluorescence lifetime (τ1), long fluorescence lifetime (τ2), and  
contribution of free conformations of NAD(P)H and FAD 2 days after treatment ...............105 
A.2 The heterogeneity index was calculated for the short fluorescence lifetime (τ1), 
long fluorescence lifetime (τ2), and contribution of free conformations of NAD(P)H  
and FAD .................................................................................................................................106 
A.3 ViSNE heat maps ..................................................................................................................107 
A.4 Heterogeneity analysis for FaDu cell monolayers in vitro for cetuximab and  
cisplatin treatments compared with control ...........................................................................108 
 
B.1 Untreated organoids and in vivo tumor tissue exhibit distinct NAD(P)H and  
FAD fluorescence lifetime components.................................................................................109 
B.2 NAD(P)H and FAD fluorescence lifetime components characterize cells in  
untreated organoids with low levels of NAD(P)H fluorescence compared with cells  
with high levels of NAD(P)H intensity .................................................................................110 
B.3 NAD(P)H and FAD fluorescence lifetime components were quantified in organoids  
after 1 day of treatment ..........................................................................................................111 
 
C.1 Cyanide characterization .......................................................................................................120 
C.2 Cell line characterization .......................................................................................................121 
C.3 Flow sorting...........................................................................................................................123 
C.4 Brightfield microscopy validates cell sorting........................................................................124 
C.5 Fluorescence microscopy validation of flow sorting a mixture of MDA-MB-231  
and SKBr3 cells .....................................................................................................................125 
C.6 HER2 staining validates flow sorting....................................................................................127 
 
 
 
 
 
 
1 
 
CHAPTER 1 
INTRODUCTION 
 
1.1 Motivation 
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cancer by 
incidence in the world [1]. Each year, 500,000 new cases are diagnosed with a five-year survival 
rate between 40-50% [1]. Current standards of care for HNSCC patients include surgery, 
radiation therapy, and chemotherapy. However, surgeries often cause serious morbidities by 
impairing the ability to speak, chew, and swallow. Additionally, radiation therapy and 
chemotherapy introduce toxicities causing nausea, diarrhea, rash, dry mouth or thickened saliva, 
and changes in taste [2]. These negative side effects from HNSCC treatment justify the need for 
improved treatments and the development of biomarkers of early treatment efficacy.  
Current treatments cure only 50-60% of HNSCC patients [3]. Measures of treatment 
response in HNSCC include x-ray computed tomography (CT), magnetic resonance imaging 
(MRI), and positron emission tomography (PET). However, these methods are only effective 
weeks to months after treatment begins and require contrast agents and/or expensive equipment. 
Additionally, tumor heterogeneity can contribute to treatment resistance, so single cell 
measurements would be beneficial to identify resistant cell subpopulations. Alternative treatment 
options for non-responders include re-irradiation, chemotherapy, or surgery [4]. Early predictors 
of drug efficacy would reduce toxicities, costs, and time associated with ineffective therapy. 
Therefore, there is a need for a cost-effective, noninvasive tool to determine treatment response 
at an early timepoint.  
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Therapeutic interventions for HNSCC include traditional chemotherapy and targeted 
inhibitors. Cisplatin is a common chemotherapy used in HNSCC [5]. In the past decade, targeted 
inhibitors have been developed to treat HNSCC. More than 90% of HNSCC cases exhibit 
upregulation of epidermal growth factor receptor (EGFR). The EGFR signaling pathway drives 
cell proliferation, growth, and survival. EGFR is the only proven molecular target for HNSCC 
therapy [4]. Cetuximab is a monoclonal antibody that inhibits EGFR activation, but clinical 
outcomes with cetuximab treatment have been poor and are not correlated with EGFR protein 
expression levels [6]. Improved technologies could guide the selection of drugs for individual 
patients so that alternative treatments can be administered. 
The EGFR signaling pathway regulates cellular metabolism, including glycolysis and 
oxidative phosphorylation. Cancer often exhibits altered metabolism, particularly increased 
aerobic glycolysis (Warburg effect) [7], and metabolic pathways involve the autofluorescent 
cofactors NAD(P)H and FAD. The optical redox ratio and fluorescence lifetimes of NAD(P)H 
and FAD exploit intrinsic contrast to measure cellular metabolism at high resolution.  
The overall goal of this dissertation is to enable improved response to therapy in head and 
neck cancer patients. Specifically, in vitro and in vivo models of head and neck cancer are treated 
with chemotherapy and targeted drugs, and endogenous fluorescence is measured from 
NAD(P)H and FAD, which are cofactors in glycolysis and oxidative phosphorylation. 
Ultimately, this technique could be applied to improve drugs and treatment regimens for head 
and neck cancer patients. 
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1.2 Specific Aims 
A method to predict drug efficacy could enable optimal drug selection for individual 
HNSCC patients, thereby improving patient outcomes. Additionally, a method to monitor 
therapeutic effects at early timepoints after treatment onset would identify ineffective treatments. 
Molecular targets of HNSCC treatment include epidermal growth factor receptor (EGFR). EGFR 
participates in cellular signaling pathways that regulate metabolic cofactors including NAD(P)H 
and FAD, which are autofluorescent molecules involved in glycolysis and oxidative 
phosophorylation. The optical redox ratio is defined as the fluorescence intensity of NAD(P)H 
divided by that of FAD, and provides a global measure of metabolism. The fluorescence lifetime 
is a complementary optical measure that reports on the molecular microenvironment (protein-
binding) of NAD(P)H and FAD. These fluorescence lifetimes and the optical redox ratio are 
parameters for “optical metabolic imaging”.  
Hypothesis: Optical metabolic imaging is sensitive to treatment response in HNSCC. 
Aim 1 - Characterize optical metabolic parameters in head and neck cancer cell lines early after 
treatment with approved and experimental drugs. Feasibility will be established using human 
HNSCC cell lines. Cells will be treated with the clinically approved EGFR-targeting antibody 
cetuximab, the clinically approved chemotherapy cisplatin, or the experimental phosphoinositide 
3-kinase (PI3K)/mammalian target of rapamycin (mTOR)-inhibitor BGT226 for 24 hours. 
NAD(P)H and FAD autofluorescence intensities and lifetimes will be characterized compared 
with control cells. Gold standard analysis will validate molecular targeting of cetuximab and 
BGT226 (western blot) and measure metabolic treatment response (lactate production/glucose 
consumption, proliferation).  
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Aim 2 - Determine optical metabolic response to treatment in vivo in mouse xenografts using 
human head and neck cancer cells. Male nu/nu mice will be injected with head and neck cancer 
cells. Once tumors reach ~100mm
3
 the mice will be treated with cetuximab, cisplatin, or their 
combination. NAD(P)H and FAD autofluorescence intensities and lifetimes will be measured 48 
hours after treatment, and cell subpopulation analysis will characterize tumor heterogeneity. 
Tumor growth over time, cell proliferation, and cell death will be used as gold standard measures 
of response.  
Aim 3 – Translate optical metabolic imaging to head and neck cancer patient tissues. Human 
patient tissues of head and neck cancer will be acquired for ex vivo imaging. Samples will 
include tissue from multiple anatomical sites and cell types. Fluorescence lifetime images of 
NAD(P)H and FAD will probe tissue morphology and metabolism. Second harmonic generation 
(SHG) microscopy will image extracellular matrix composition, particularly collagen density and 
alignment. 
Aim 4 - Quantify optical metabolic parameters in organoid in vitro model of head and neck 
cancer after treatment. Head and neck cancer xenografts will be excised, digested, and grown in 
culture (organoids). Metabolic phenotypes of organoids will be characterized alone and after 
treatment with cetuximab, cisplatin, or their combination. NAD(P)H and FAD autofluorescence 
intensities and lifetimes will be measured 24 hours after treatment. Additionally, cellular 
heterogeneity of organoids based on optical metabolic imaging parameters will be analyzed. 
Gold standard tumor response curves will be measured. 
Impact: Optical metabolic imaging has potential to predict optimal drugs for HNSCC patients, 
enabling improved patient outcomes. Additionally, early measurement of response could identify 
ineffective treatment regimens, reducing unnecessary morbidities, toxicities, and costs. 
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1.3 Dissertation Outline 
Chapter 1 explains the motivation behind this dissertation work. Chapter 2 provides 
relevant background information, particularly for head and neck cancer, methods for measuring 
treatment response, and optical techniques. The autofluorescence properties of NAD(P)H and 
FAD, as well as the roles of NAD(P)H and FAD in cell metabolism, are described. Chapter 3 
characterizes optical metabolic imaging parameters, including the optical redox ratio and 
fluorescence lifetimes of NAD(P)H and FAD, in head and neck cancer cell lines after treatment 
with chemotherapy and targeted drugs. These optical parameters were compared with gold 
standard measures of cellular metabolism and therapeutic response. These studies provide a 
foundation for measurements in more complex systems. Chapter 4 shows feasibility of the 
optical redox ratio and fluorescence lifetime measurements of NAD(P)H and FAD in vivo for 
head and neck cancer xenografts to resolve response early after treatment. Chapter 5 translates 
optical metabolic imaging for ex vivo patient tissues of head and neck cancer. This study 
characterizes metabolic, morphologic, and structural properties on fresh, unprocessed human 
tissue from a variety of anatomical sites and cell types. Chapter 6 develops a protocol for 
generating three-dimensional organoid cultures from head and neck cancer tissue and 
characterizes the optical metabolic imaging properties of the organoids alone and after drug 
treatment. This type of physiologically-relevant in vitro model could provide a platform for 
streamlining drug discovery and predicting optimum treatments before administering drugs to 
individual patients. Chapter 7 presents the conclusions from this work, as well as future 
directions, contributions to the field, and broader impacts. 
Appendices A and B include supplementary information for Chapters 4 and 6, 
respectively. Appendix C characterizes flow cytometry signals of cellular autofluorescence for 
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breast cancer cells with distinct phenotypes and applies flow sorting to separate heterogeneous 
samples into distinct cell subpopulations. 
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CHAPTER 2 
BACKGROUND 
 
Shah AT. 2013. Autofluorescence Imaging Reflects Metabolic Response to  
Treatment in Human Head and Neck Squamous Cell Carcinoma (Master’s Thesis). Vanderbilt 
University 
 
2.1 Anatomy and Physiology of the Head and Neck  
The head and neck region includes the nasal cavity, oral cavity, pharynx, and larynx 
(Figure 2.1) [1]. These organs work together to perform critical functions, including chewing and 
swallowing food, speaking, and breathing.  
 
 
Figure 2.1. Anatomy of the head and neck region. Head and neck squamous cell carcinoma 
originates in squamous cells of the oral cavity, nasal cavity, pharynx, and larynx [8]. 
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The oral cavity includes the lips, teeth, jaw, tongue, roof of the mouth, floor of the mouth, 
and salivary glands. The lips form the opening of the mouth and they are important in speech and 
containing food in the mouth. The tongue helps guide food and contains taste buds. The main 
function of the oral cavity is to chew and break down food mechanically using teeth and 
chemically using saliva produced by salivary glands.  
The pharynx is a five-inch long tube located between the nose and the esophagus, and it 
consists of the nasopharynx, oropharynx, and hypopharynx. This cavity in the throat connects the 
nasal and oral cavities with the rest of the respiratory and digestive system, including the 
stomach, small intestine, and large intestine. Swallowing occurs in the pharynx, moving food 
from the mouth into the esophagus.  
The larynx is situated below the pharynx. It is also called the voice box because it 
contains vocal chords that create sound and control pitch and volume. During swallowing, the 
larynx is elevated and the vocal chords move towards each other to move food through the 
esophagus and prevent it from going into the trachea, which leads to the lungs. The epiglottis, a 
layer of cartilage, moves over the laryngeal opening to prevent food from going into the 
respiratory pathways. The esophagus connects the pharynx to the stomach, where food is stored 
and broken down.  
 
Prevalence and Diagnosis of Head and Neck Squamous Cell Carcinoma 
 Head and neck squamous cell carcinoma (HNSCC) originates in squamous cells of the 
oral cavity, nasal cavity, pharynx, and larynx. The hallmarks of cancer include evading 
apoptosis, self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue invasion 
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and metastasis, and limitless replicative potential [9]. More than 90% of head and neck cancers 
are squamous cell carcinoma [10].  
Incidence and mortality of HNSCC is correlated with long-term use of tobacco and 
alcohol. About 75% of HNSCC incidence occurs in men compared with 25% in women [11]. 
The stereotypical HNSCC patient is above 50 years old, but the younger population of HNSCC 
patients is increasing. In particular, this increase has been attributed to the prevalence of human 
papilloma virus (HPV), which affects about 25% of HNSCC cases [12][13]. Additionally, poor 
diet, particularly lacking vitamin A and iron, and poor oral hygiene can increase risk for 
developing HNSCC [14]. 
Early symptoms of HNSCC are usually vague. Symptoms of cancer in the oral cavity 
include persistent abnormal masses and sores [2]. Symptoms of cancer in the oropharynx, 
hypopharynx, and larynx include difficulty swallowing, sore throat, and hoarseness or other 
changes in voice quality. Symptoms of cancer in the nasal cavity include difficulty breathing 
through the nose and inflammation of the sinuses [15]. Screening is conducted using physical 
examination to inspect ulcers within the mouth and throat, palpation of the neck, and endoscopy. 
Additionally, magnetic resonance imaging (MRI), x-ray, and computed tomography (CT) can be 
used to detect HNSCC [16]. HNSCC is diagnosed by pathologic examination of surgical biopsy. 
Unfortunately, most cases are diagnosed at advanced stages, so effective treatment options are 
crucial to prevent unnecessary mortality and morbidity. 
 
Treatment Methods for Head and Neck Cancer 
 Treatment techniques for HNSCC depend on the stage, location, and resectability of the 
primary tumor. Early stages are usually treated with surgery to remove tumor-containing tissue 
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and radiation, while advanced stages are treated with surgery and radiation in combination with 
chemotherapy, including cisplatin and fluorouracil (FU). Targeted therapies have also been 
investigated. HNSCC exhibits upregulation of epidermal growth factor receptor (EGFR) in more 
than 90% of cases [17]. EGFR activation leads to growth and proliferation of epithelial cells 
(Figure 2.2). Cetuximab is a monoclonal antibody that binds to EGFR, prevents activation, and 
leads to receptor degradation, and it has been used to inhibit EGFR-expressing tumors. 
Cetuximab is approved in combination with radiation therapy in patients with locally advanced 
HNSCC. However, since only a portion of patients respond to EGFR inhibitors, downstream 
targets have the potential to improve patient outcomes. Commonly mutated targets include 
phosphoinsitide 3-kinase (PI3K), signal transducer and activator of transcription 3 (STAT3), 
mammalian target of rapamycin (mTOR), Akt, vascular endothelial growth factor receptor 
(VEGFR), NF-κB, and human epidermal growth factor receptors 2 (HER2) and 3 (HER3) [18] 
[19]. 
 
Figure 2.2. EGFR signaling pathway. EGFR activates pathways promoting cell survival and 
proliferation [20]. 
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Current treatment options introduce toxicities and complications that impair the patient’s 
quality of life. Surgeries often lead to serious morbidities, including difficulty or inability to 
speak and swallow, swelling, and changes in appearance. Therefore, organ preservation and 
function preservation are important considerations in HNSCC treatment. Additionally, 
radiotherapy and chemotherapy cause side effects, such as nausea, diarrhea, rash, dry mouth or 
thickened saliva, or changes in taste [2]. HNSCC can be aggressive depending on the location 
and proximity to lymph nodes, increasing the capability to metastasize [21]. The 5-year survival 
rate for HNSCC patients is between 40-50% [1]. Despite advancements and improvements in 
surgical techniques, chemotherapy, and radiation delivery, long-term survival has not improved 
[22]. The current standard to measure cancer treatment response includes whole-body imaging 
methods, like CT, x-ray, MRI, and positron emission tomography (PET).  
 
Optical Techniques for Head and Neck Squamous Cell Carcinoma 
HNSSC is an ideal target for optical imaging because of easy access to the site using fiber 
optic probes [23][24]. Additionally, fiber optics can be incorporated into endoscopes that are 
currently in use. 
Optical techniques have been investigated to detect HNSCC. High-resolution 
microendoscopic imaging has been used to distinguish cancerous versus benign sites for 
assessing tumor margins in surgery for HNSCC [23]. Reflectance spectroscopy using polarized 
light has also been shown to non-invasively extract morphologic information to detect neoplasia 
in epithelial tissue phantoms and oral tissue in vivo [25]. Additionally, fluorescence spectroscopy 
has been shown to identify oral neoplasias with sensitivities and specificities greater than 88% 
[26]. Muller, et al. combined intrinsic fluorescence spectroscopy, diffuse reflectance 
12 
 
spectroscopy, and light scattering spectroscopy and achieved a sensitivity and specificity of 96% 
and 96% in distinguishing dysplasia from normal tissue in HNSCC patients [27]. Contrast 
agents, particularly acetic acid, and blue-white light have been used to identify premalignancy in 
the oral cavity, but clinical studies will be required to determine the sensitivity and specificity of 
these techniques [28]. Furthermore, the autofluorescence intensity of NAD(P)H and FAD has 
been used to distinguish normal from dysplasia in oral tissue [29], and the NAD(P)H and FAD 
fluorescence lifetimes have been shown to identify precancer compared with normal in the 
DMBA-treated hamster cheek pouch model [30][31][32][33]. Optical coherence tomography has 
also been applied with fluorescence lifetime imaging to discriminate normal from cancer in the 
hamster cheek pouch [34]. Multiphoton microscopy of endogenous fluorescence has been used 
to quantify cellular and tissue morphology in the DMBA-treated hamster cheek pouch model 
[35][36]. 
Attempts have been made to monitor treatment response in HNSCC using fluorescently-
labeled antibodies. In one study, mice with HNSCC xenografts treated with fluorescently-labeled 
cetuximab decreased in tumor volume, but tumor fluorescence did not correlate with response to 
treatment [37]. Gleysteen et al. used a similar approach of growing xenografts and treating the 
mice with fluorescently labeled cetuximab, cisplatin, and radiation. They found no change 
among fluorescence intensity before treatment, after six weeks of treatment, or at ten weeks of 
treatment, although tumor regression was observed based on histological analysis. This indicates 
that fluorescence intensity of labeled cetuximab does not reflect tumor response [38]. However, 
endogenous fluorescence has not been studied to measure treatment response in HNSCC.  
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Two-Photon Fluorescence Microscopy and Fluorescence Lifetime Imaging 
 Light can be described as packets of energy in photons. Fluorescence occurs when a 
molecule absorbs a photon of a particular energy and emits a photon of a different energy [39]. 
This absorption excites the molecule from the ground state, S, to the excited state, S*, and upon 
relaxation the emitted light has an energy less than the absorbed energy (Figure 2.3). Energy and 
wavelength are inversely related according to E = hc/λ, where E represents energy, h represents 
Planck’s constant, λ represents wavelength, and c represents the speed of light. Therefore, a 
lower energy corresponds to a longer wavelength. Endogenous fluorophores, including 
NAD(P)H, FAD, tryptophan, collagen, and elastin, occur naturally in the body, and probing 
these can eliminate the need for dyes or contrast agents [40].  
Two-photon excitation occurs by simultaneous absorption of two photons with half the 
energy required for single-photon excitation (Figure 2.3) [41]. Photons with half the energy 
correspond to twice the wavelength. Most endogenous fluorophores are excited in the ultraviolet 
(UV) to visible range (~300-500nm), so therefore two-photon excitation uses near-infrared (NIR) 
light (~700-900nm) for excitation [40]. UV or visible light is constrained to a penetration depth 
of about 100µm below tissue surface, whereas decreased scattering and absorption for NIR light 
allows for deeper penetration [42]. Additionally, since the absorption of two photons is required 
for excitation, sufficient photon flux is only present at the focal point, whereas single-photon 
excitation can produce fluorescence outside the focal point due to scattering (Figure 2.4). This 
allows for precise depth-sectioning and elimination of out-of-focus signal.  
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Figure 2.3. Absorption and fluorescence emission energy diagram. Single-photon (blue) and two-
photon (red) excitation causes fluorescence emission (green) [43].  
 
 
Figure 2.4. Comparison between single-photon and two-photon excitation. Single-photon 
fluorescence causes excitation at the focal point and outside the focal point (top), whereas two-
photon fluorescence causes excitation only at the focal point (bottom) [44].  
 
Fluorescence lifetime imaging probes the amount of time that a fluorophore is in the 
excited state before relaxing to the ground state [39][45]. The lifetime is sensitive to the 
microenvironment, including protein-binding, pH, and oxygen. In particular, the lifetime 
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discriminates between free and protein-bound conformations of molecules. To calculate the 
lifetime, a histogram of the lifetime events is plotted and fit to an exponential curve. The number 
of components in the exponential curve depends on the number of molecular species or binding 
configurations present. For example, NAD(P)H and FAD exist in free and protein-bound 
conformations, so these lifetime histograms are fit to a two-component exponential function: F(t) 
= α1e
-t/τ1
+ α2e
-t/τ2, where F represents the fluorescence as a function of time, α represents the 
contribution from each component and τ represents the lifetime of each component (Figure 2.5). 
The lifetime occurs on the order of picoseconds to nanoseconds. Applying two-photon 
fluorescence and fluorescence lifetime imaging of the metabolic cofactors NAD(P)H and FAD 
can provide insight into cellular metabolism and microenvironment in vitro and in vivo [46]. 
 
Figure 2.5. Fluorescence lifetime decay curve. The fluorescence lifetime is calculated by fitting 
the lifetime events (blue) to an exponential function (red). 
 
Cellular Metabolism and Tumor Heterogeneity 
During glycolysis, NAD
+
 is reduced to nicotinamide adenine dinucleotide (NADH) 
(Figure 2.6). During oxidative phosphorylation, NADH is oxidized to NAD
+
 and FADH2 is 
oxidized to flavin adenine dinucleotide (FAD). NADH and FAD exhibit autofluorescence, 
whereas NAD
+
 and FADH2 do not. Additionally, NADH and FAD can be separated spectrally 
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based on their optimal excitation and emission wavelengths. NADPH exhibits similar 
fluorescence excitation and emission properties as NADH, so fluorescence from these molecules 
is termed NAD(P)H. NADPH is expected to contribute a low background signal because the 
concentration of NADH is about 5 times higher than NADPH [47], NADH has a 1.25 to 2.5 
times higher quantum yield than NADPH [48], and metabolic perturbations have been shown to 
primarily affect NADH [49]. 
 
 
Figure 2.6. The role of NADH and FAD in cellular metabolism. Glycolysis occurs in the cell 
cytoplasm, whereas the Kreb’s cycle and the electron transport chain occur in the mitochondria 
[50]. 
 
The optical redox ratio, defined as the fluorescence intensity of NAD(P)H divided by the 
fluorescence intensity of FAD is an established method for probing cellular metabolism 
[46][51][52]. For example, the redox ratio has been shown to be higher for cancer cells 
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compared with nonmalignant cells [53], which can be attributed to increased aerobic glycolysis 
in cancer. As a more sensitive measure, the fluorescence lifetime is the time a fluorophore stays 
in the excited state before relaxing to the ground state and reflects fluorophore 
microenvironment, including protein-binding and preferred metabolic pathways [39]. These 
measurements are advantageous because they use intrinsic contrast to probe cellular metabolism 
and can be applied on a single cell level. 
 Tumors can contain multiple subpopulations of cancer cells with different phenotypes 
and sensitivities to treatment [54][55], and this tumor heterogeneity can impact treatment 
response. In particular, subpopulations of cells that are resistant to treatment can continue to 
proliferate after therapy and be responsible for patient relapse. For example, previous work has 
shown that a minority subset of cells can drive tumor growth in HNSCC [56]. However, current 
methods for planning treatment regimens include targeting the majority population of cells [57]. 
Therefore, single cell measurements have potential to resolve cellular subpopulations and 
identify treatment-resistant cells that drive patient relapse.  
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CHAPTER 3 
OPTICAL METABOLIC IMAGING OF TREATMENT RESPONSE IN HUMAN HEAD 
AND NECK SQUAMOUS CELL CARCINOMA 
 
Shah AT, Demory Beckler M, Walsh AJ, Jones WP, Pohlmann PR, Skala MC. “Optical 
Metabolic Imaging of Treatment Response in Human Head and Neck Squamous Cell 
Carcinoma.” PLOS ONE, 2014; 9(3) e90746 
 
3.1 Abstract 
 Optical metabolic imaging measures fluorescence intensity and lifetimes from metabolic 
cofactors nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FAD). 
These molecular level measurements provide unique biomarkers for early cellular responses to 
cancer treatments. Head and neck squamous cell carcinoma (HNSCC) is an attractive target for 
optical imaging because of easy access to the site using fiber optic probes. Two HNSCC cell 
lines, SCC25 and SCC61, were treated with Cetuximab (anti-EGFR antibody), BGT226 
(PI3K/mTOR inhibitor), or cisplatin (chemotherapy) for 24 hours. Results show increased redox 
ratio, NADH α1 (contribution from free NADH), and FAD α1 (contribution from protein-bound 
FAD) for malignant cells compared with the nonmalignant cell line OKF6 (p<0.05). In SCC25 
and SCC61 cells, the redox ratio is unaffected by cetuximab treatment and decreases with 
BGT226 and cisplatin treatment (p<0.05), and these results agree with standard measurements of 
proliferation rates after treatment. For SCC25, NADH α1 is reduced with BGT226 and cisplatin 
treatment. For SCC61, NADH α1 is reduced with cetuximab, BGT226, and cisplatin treatment. 
Trends in NADH α1 are statistically similar to changes in standard measurements of glycolytic 
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rates after treatment. FAD α1 is reduced with cisplatin treatment (p<0.05). These shifts in optical 
endpoints reflect early metabolic changes induced by drug treatment. Overall, these results 
indicate that optical metabolic imaging has potential to detect early response to cancer treatment 
in HNSCC, enabling optimal treatment regimens and improved patient outcomes. 
 
3.2 Introduction 
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cancer by 
incidence in the world [1]. Each year, 500,000 new cases are diagnosed with a five-year survival 
rate between 40-50% [1]. Current standards of care for HNSCC patients involves 
multidisciplinary care, including surgery, radiation therapy, chemotherapy, and rehabilitation. 
Treatment is intense since it is frequently delivered with curative aims. Resultant toxicities 
comprise nausea, vomiting, diarrhea, neuropathy, skin rash, dry mouth or thickened saliva, 
changes in taste, hypothyroidism, as well as impaired ability to speak, chew, and swallow 
[2][58][59]. These negative side effects from HNSCC treatment justify the need for improved 
treatments and the development of biomarkers of early treatment efficacy.  
Current measures of treatment response in HNSCC include physical examination with 
endoscopy, x-ray computed tomography (CT), magnetic resonance imaging (MRI), and positron 
emission tomography (PET). Deep invasion of tumor and subtle changes to its dimensions during 
different treatment phases may not be measurable by physical exam. Imaging studies are only 
effective weeks to months after treatment begins and require contrast agents and/or expensive 
equipment. Therefore, these methods have low sensitivity to detect beneficial effects of treatment 
before several weeks have elapsed since treatment onset. Alternative treatment options for non-
responders include re-irradiation, chemotherapy, or surgery [4]. Early predictors of drug efficacy 
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would reduce toxicities, costs, and time associated with ineffective therapy. Therefore, there is a 
need for a cost-effective, noninvasive tool to determine treatment response at an early time point.  
Therapeutic interventions for HNSCC include traditional chemotherapy and molecularly 
targeted inhibitors.  Cisplatin is a common chemotherapy used in HNSCC [5]. In the past decade, 
targeted inhibitors have been developed to treat a number of solid tumors, including HNSCC. 
More than 90% of HNSCC cases exhibit upregulation of epidermal growth factor receptor 
(EGFR). The EGFR signaling pathway drives cell proliferation, growth, and survival. EGFR is 
the only proven molecular target for HNSCC therapy [4]. Cetuximab is a monoclonal antibody 
that effectively occludes ligand binding to EGFR, thereby inhibiting receptor activation, but 
clinical outcomes with cetuximab treatment vary and are not correlated with EGFR protein 
expression levels [6]. Therefore, downstream effectors, including phosphatidylinositol 3-kinase 
(PI3K) and mammalian target of rapamycin (mTOR), have been investigated as potential 
therapeutic targets. PI3K, a master regulator of metabolism, is mutated in about 37% of HNSCC 
[60]. BGT226 is a PI3K/mTOR inhibitor currently under clinical investigation for solid tumors 
[61]. However, there is a need for improved technologies to guide the selection of drugs for 
individual patients, so that alternative treatments such as BGT226 can be used at an early time 
point. 
The EGFR and PI3K/mTOR signaling pathways regulate cellular metabolism, including 
glycolysis and oxidative phosphorylation [62]. Cancer often exhibits altered metabolism, 
particularly increased aerobic glycolysis (Warburg effect) [7]. During glycolysis, NAD
+
 is 
reduced to nicotinamide adenine dinucleotide (NADH). During oxidative phosphorylation, 
NADH is oxidized to NAD
+
 and FADH2 is oxidized to flavin adenine dinucleotide (FAD). 
NADH and FAD exhibit autofluorescence, whereas NAD
+
 and FADH2 do not. The optical redox 
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ratio, defined as the fluorescence intensity of NADH divided by the fluorescence intensity of 
FAD, reflects relative amounts of glycolysis compared with oxidative phosphorylation and is an 
established method for probing cellular metabolism [46][51][52]. The fluorescence lifetime is the 
time a fluorophore stays in the excited state before relaxing to the ground state and reflects 
fluorophore microenvironment, including protein-binding and preferred metabolic pathways 
[39]. The optical redox ratio and fluorescence lifetimes of NADH and FAD exploit intrinsic 
contrast to measure optical endpoints of cellular metabolism. Furthermore, metabolic endpoints 
show particular promise because shifts in cellular metabolism often occur sooner than changes in 
tumor volume or glucose uptake. 
Tissue autofluorescence has been previously used to detect HNSCC. The 
autofluorescence intensity of NADH and FAD has been used to distinguish normal from 
dysplasia in oral tissue [29], and the NADH and FAD fluorescence lifetimes have been shown to 
identify precancer compared with normal in the DMBA-treated hamster cheek pouch model 
[31][32][33][30]. Multiphoton microscopy of endogenous fluorescence has been used to quantify 
cellular and tissue morphology in the DMBA-treated hamster cheek pouch model [35][36]. 
However, no previous literature has characterized endogenous fluorescence in response to 
treatment in HNSCC. Fluorescent dyes have been used to monitor anti-EGFR antibody uptake in 
HNSCC, but results did not reflect response in vivo [37][38]. Optical metabolic imaging is 
sensitive to early metabolic shifts after cancer treatment and has potential to noninvasively detect 
treatment response sooner than current methods. 
The serious morbidities and toxicities from HNSCC treatment, as well as treatment 
failures, justify the need for early predictors of treatment efficacy. This study tests the hypothesis 
that autofluorescence from metabolic cofactors NADH and FAD can resolve response to targeted 
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therapies and chemotherapy in HNSCC. Optical metabolic imaging was performed on two 
HNSCC cell lines, SCC25 and SCC61, treated for 24 hours with targeted drugs (cetuximab or 
BGT226) or chemotherapy (cisplatin). HNSCC is an ideal site for optical imaging because of 
easy access to the site with fiber optic probes. These results indicate that optical metabolic 
imaging has potential to expedite drug screenings, develop optimal treatments, and improve 
patient outcomes for HNSCC.  
 
3.3 Materials and Methods 
Cell Culture and Reagents 
The TERT-immortalized human oral keratinocyte line OKF6/TERT-1 (OKF6) [63], the 
squamous cell carcinoma line SCC25 [64][65][66][67], and the squamous cell carcinoma line 
SCC61 [66] were acquired from J. Rheinwald and the Cell Culture Core of the Harvard Skin 
Disease Research Center, Boston, MA. OKF6 cells were cultured in keratinocyte serum-free 
medium (GIBCO K-sfm; Invitrogen) supplemented with 25µg/ml bovine pituitary extract, 1% 
penicillin/streptomycin, 0.2ng/ml epidermal growth factor, and 0.3mM CaCl2. SCC25 and 
SCC61 cells were cultured in DMEM/F12 media (Invitrogen) supplemented with 10% fetal 
bovine serum and 0.4µg/ml hydrocortisone (Sigma).  
For fluorescence imaging, 10
5
 cells were plated on 35 mm glass-bottomed dishes 
(MatTek Corp.). The media was replaced 24 hours after plating with control media or treatment 
media containing 13nM cetuximab (Vanderbilt Pharmacy), 300nM NVP-BGT226 
(Selleckchem), or 176µM cisplatin (Selleckchem). The drug doses were chosen to be 11 times 
the IC50 for each  drug [3] [68] [69]. The cells were imaged 24 hours after treatment.  
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Imaging Instrumentation 
Fluorescence lifetime images were collected using a custom-built multi-photon fluorescence 
microscope (Prairie Technologies). Images were acquired through an inverted microscope (TiE, 
Nikon) with a 40x oil immersion objective (1.3 NA). Fluorescence was excited using a 
titanium:sapphire laser (Chameleon, Coherent Inc.) and collected using a GaAsP photomultiplier 
tube (H7422P-40, Hamamatsu). NADH and FAD images were acquired sequentially for the 
same field of view. NADH fluorescence was isolated using an excitation wavelength of 750nm 
and an emission bandpass filter of 400-480nm. FAD fluorescence was isolated using an 
excitation wavelength of 890nm and an emission bandpass filter of 500-600nm. The average 
power incident on the sample was approximately 10mW. The acquired images consisted of 256 x 
256 pixels (170µm x 170µm) with a 4.8µs pixel dwell time. Time-correlated single photon 
counting (TCSPC) electronics (SPC-150, Becker and Hickl) were used to collect fluorescence 
lifetime images over 60 seconds. The approximate rate of photon counting was 1-2*10
5
 
photons/second. The absence of photobleaching was confirmed by monitoring photon count rates 
throughout image acquisition.  
The instrument response function (IRF) was measured from second harmonic generation 
of urea crystals excited at 900nm, and the full width at half maximum (FWHM) was calculated 
to be 244 ps. A Fluoresbrite YG microsphere (Polysciences Inc.) was imaged as a daily standard. 
The lifetime decay curves were fit to a single exponential decay and the fluorescence lifetime 
was measured to be 2.13 ± 0.28ns (n=7), which is consistent with published values [32][70]. 
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Cyanide Perturbation 
The OKF6 cells were plated at a density of 10
5
 cells per 35 mm glass-bottomed dish (MatTek 
Corp.). After 48 hours, fluorescence lifetime images of NADH and FAD were acquired. Then, 
the media was replaced with cyanide-supplemented media (4mM NaCN, Sigma). After five 
minutes of cyanide treatment, fluorescence lifetime images of NADH and FAD were acquired.  
 
Image Analysis 
Fluorescence lifetime images were analyzed using SPCImage software (Becker and Hickl). 
Binning included the selected pixel and the eight surrounding pixels. The fluorescence lifetimes 
were calculated by de-convolving the measured fluorescence decay curve with the IRF and 
fitting to a two-component exponential curve, F(t) = α1e
-t/τ1 + α2e
-t/τ2 
+ c. F(t) represents the 
fluorescence intensity as a function of time after the excitation pulse, τ1 and τ2 represent the short 
and long fluorescence lifetimes, respectively, α1 and α2 represent the contribution from each 
lifetime component (α1+α2=1), and c represents background light. A two-component decay curve 
was chosen to represent free and protein-bound conformations of NADH and FAD [32]. The 
weighted mean lifetime, τm, was calculated, τm = α1τ1+α2τ2. The photon counts per pixel were 
summed over the 60 second collection time to calculate a fluorescence intensity image. A 
threshold was applied to exclude fluorescence from background and cell nuclei. The 
fluorescence intensities and lifetime values were imported into MATLAB (Mathworks) for 
further quantification. Redox ratio images were calculated by dividing the fluorescence intensity 
image of NADH by the fluorescence intensity image of FAD for the same field of view, and the 
average per image was computed. The redox ratio was normalized to control cells for comparing 
treatment groups within cell lines. The redox ratio was normalized to the nonmalignant OKF6 
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cells when comparing between cell lines. Average fluorescence lifetime values were calculated 
per image. For the control groups 30 images were analyzed, and for the treatment groups 18 
images were analyzed. 
 
Western Blotting Analysis 
Cells were plated at 3*10
6
 cells per 10cm dish. After 24 hours, the media was removed, the cells 
were washed three times with phosphate buffered saline (PBS), and serum-free media was 
added. After another 24 hours, the media was replaced with treatment media for one hour. For 
the groups treated with epidermal growth factor (EGF) or transforming growth factor alpha 
(TGF-α), 10ng/mL EGF or TGF-α was added for 5 minutes. The cells were lysed with lysis 
buffer (1% Triton X-100, 10% Glycerol, 50 mM HEPES pH 7.2, and 100 mM NaCl) 
supplemented with sodium orthovanadate and protease inhibitor cocktail. Proteins were 
separated using a 10% SDS-PAGE separation gel at 100V. The gel was transferred at 27V 
overnight to a PVDF membrane. The membrane was blocked using 5% bovine serum albumin 
(BSA) for one hour and then incubated in the following primary antibodies overnight: EGFR 
(Millipore, 1:1000), pY1173 EGFR (Cell Signaling, 1:250), AKT (Cell Signaling, 1:250), pS473 
AKT (Cell Signaling, 1:250), or GAPDH (Sigma, 1:1000). Membranes were washed four times, 
secondary antibodies were added for one hour, and electrogenerated chemiluminescence (ECL) 
was used to measure luminescence. 
 
Proliferation Assay 
Cells were plated in a 96 well plate at 3.3*10
3
 cells per well. Four wells per treatment group 
were plated. After 24 hours, the media was replaced with treatment media supplemented with 
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10µM BrdU. The cells incubated for 24 hours and then were fixed with 4% paraformaldehyde 
for 15 minutes. The cells were washed twice with PBS and permeabilized with 0.3% Triton X in 
PBS for 15 minutes. The DNA was denatured using hydrochloric acid, and the cells were 
blocked using 10% goat serum and 0.3% Triton X for one hour. Primary antibody (rat anti-BrdU, 
Abcam, 1:100) was incubated overnight. The cells were washed three times with PBS and 
incubated in secondary antibody (DyLight594-conjugated goat anti-rat, Jackson 
Immunoresearch, 1:200) for two hours. The cells were washed three times with PBS and 
counterstained with Hoechst 33528 (1:1000) for 10 minutes. Fluorescence images were acquired 
for three fields of view per well (n=12), and the number of cells per image was counted 
(ImageJ). 
 
Glucose and Lactate Assays 
Cells were plated at a density of 10
5
 cells per 35 mm dish, and 24 hours later the media was 
replaced with treatment media. After 24 hours of treatment, glucose and lactate concentrations 
from four samples per group were measured according to the protocols of commercially 
available kits (Invitrogen; Eton Biosceience). 
 
Statistical Analyses 
Bar graphs are represented as mean ± standard error. Statistical significance was determined 
using two-way Wilcoxon rank sum tests in MATLAB (Mathworks). A p-value less than 0.05 
indicated statistical significance. 
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3.4 Results 
Redox ratio validation was performed by perturbing nonmalignant OKF6 cells with 4mM 
cyanide, which prevents oxidation of NADH to NAD
+
 in the electron transport chain [71]. This 
accumulation of NADH causes an increase in the optical redox ratio (Figure 3.1a) and verifies 
isolation of NADH and FAD fluorescence. The contribution from free NADH (α1) increases with 
cyanide treatment (Figure 3.1b), causing a decreased NADH mean lifetime (data not shown). 
The contribution from protein-bound FAD (α1) decreases with cyanide treatment (Figure 3.1c), 
causing an increased FAD mean lifetime (data not shown).  
 
Figure 3.1. Cyanide treatment alters redox ratio, NADH α1, and FAD α1 in nonmalignant oral 
cells (OKF6). (a) Cyanide treatment (4mM) disrupts the electron transport chain, causing an 
increase in the optical redox ratio. (b) Cyanide treatment increases the contribution of free 
NADH (α1) and (c) decreases the contribution of protein-bound FAD (α1). * p<0.05, rank sum 
test; mean ± SEM. 
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The optical metabolic endpoints differentiate the malignant cell lines, SCC25 and 
SCC61, from the nonmalignant cell line, OKF6 (Figure 3.2). The malignant cell lines showed an 
increased redox ratio compared with the OKF6 cells (p<0.05). The malignant cell lines showed 
increased NADH α1 compared with the OKF6 cells (p<0.05) and increased FAD α1 compared 
with the OKF6 cells (p<0.05), suggesting differences in metabolic pathways between the 
malignant and nonmalignant cells.  
 
Figure 3.2. Optical metabolic endpoints distinguish malignant from nonmalignant cells. (a) The 
normalized redox ratio increases for the malignant cell lines (SCC25 and SCC61) compared to 
nonmalignant cells (OKF6), indicating increased glycolysis compared with oxidative 
phosphorylation. (b-c) The contribution of free NADH and protein-bound FAD (α1) increase for 
the malignant cell lines compared with the nonmalignant cell line, reflecting shifts in metabolic 
pathways. * p<0.05, rank sum test; mean ± SEM.  
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Western blotting analysis was used to ensure target inhibition (Figure 3.3). Cetuximab 
targeting of EGFR was assessed by measuring phosphorylated tyrosine (Y) 1173 of EGFR 
(pEGFR), which is absent with cetuximab treatment. BGT226 targeting of PI3K/mTOR was 
assessed by measuring phosphorylated serine (S) 473 of Akt (pAkt) because PI3K and mTOR 
activation drive Akt activation in the PI3K/Akt signaling pathway. pAkt is absent with BGT226 
treatment. These results indicate that cetuximab and BGT226 target EGFR and PI3K/mTOR, 
respectively. Western blotting analysis was also performed to characterize the SCC25 and 
SCC61 cell lines (not shown). SCC61 cells showed increased pAkt, reflecting upregulated PI3K, 
and agreeing with published results [72]. Additionally, SCC61 cells exhibited increased EGFR 
and pEGFR compared with SCC25 cells. 
 
Figure 3.3. Western blotting analysis verifies molecular targeting of cetuximab and BGT226. 
Western blot for (a) SCC25 and (b) SCC61 cells. Epidermal growth factor (EGF) and 
transforming growth factor alpha (TGF α) activate the epidermal growth factor receptor (EGFR) 
and AKT pathways. Treatment with cetuximab decreases phosphorylated EGFR (pEGFR), and 
treatment with BGT226 decreases phosphorylated AKT (pAKT). 
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Representative images of SCC25 and SCC61 cells after 24 hours of treatment provide 
qualitative visualization of the redox ratio, NADH α1, and FAD α1 (Figure 3.4). NADH and FAD 
fluorescence from the cytoplasm was quantified across treatment groups and cell lines. The 
redox ratios of SCC25 and SCC61 cells show no significant changes with cetuximab treatment, 
and decrease with BGT226 and cisplatin treatment (Figure 3.5a). The fluorescence lifetimes of 
NADH and FAD reflect cellular microenvironment and protein-binding. NADH α1 represents the 
contribution from free NADH. For SCC25 cells, NADH α1 decreases with BGT226 and cisplatin 
treatment. For SCC61 cells, NADH α1 decreases with cetuximab, BGT226, and cisplatin 
treatment (Figure 3.5b). FAD α1 represents the contribution from protein-bound FAD. For 
SCC25 and SCC61 cells, FAD α1 decreases with cisplatin treatment (Figure 3.5c). Combined, 
these data show that optical metabolic endpoints are sensitive to treatment with cetuximab, 
BGT226, and cisplatin in SCC25 and SCC61. 
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Figure 3.4. Representative autofluorescence images after treatment. Representative images of the 
redox ratio (1st row), NADH α1 (2nd row), and FAD α1 (third row) for (a) SCC25 cells and (b) 
SCC61 cells treated with control (1st column), cetuximab (2nd column), BGT226 (3rd column), 
or cisplatin (4th column). α1 quantifies the short lifetime component (α1+α2=1). NADH α1 
represents the contribution from free NADH, while FAD α1 conversely represents the 
contribution from protein-bound FAD. Scale bar represents 30um. 
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Proliferation was quantified as a standard measure of treatment response. Cetuximab 
treatment does not induce a statistically significant effect on proliferation, whereas BGT226 and 
cisplatin treatment decrease proliferation (Figure 3.5d).  Additionally, glycolytic rates were 
quantified after treatment. SCC25 shows decreased lactate production/glucose consumption with 
BGT226 and cisplatin treatment, and SCC61 shows decreased lactate production/glucose 
consumption with cetuximab, BGT226, and cisplatin treatment (Figure 3.5e). 
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Figure 3.5. Metabolic endpoints measure response in SCC25 and SCC61 after treatment. (a) 
SCC25 and SCC61 cells were treated with cetuximab, BGT226, or cisplatin for 24 hours. The 
optical redox ratio is defined as the fluorescence intensity of NADH divided by that of FAD and 
is normalized by the redox ratio from control cells per day. Treatment with cetuximab does not 
affect the normalized redox ratio. Treatment with BGT226 or cisplatin decrease the normalized 
redox ratio. α1 represents the contribution of the short fluorescence lifetime (free conformation 
for NADH and protein-bound conformation for FAD) (α1+α2=1). (b) NADH α1 decreases after 
treatment with BGT226 and cisplatin in SCC25 cells and after treatment with cetuximab, 
34 
 
BGT226, and cisplatin in SCC61 cells. (c) FAD α1 decreases after treatment with cisplatin in 
SCC25 and SCC61 cells. (d) Cells were treated for 24 hours and proliferating cells were labeled 
with BrdU. The ratio of proliferating cells was calculated by dividing the number of BrdU-
labeled cells by the total number of cells per image. Treatment with cetuximab does not affect 
proliferation. Treatment with BGT226 or cisplatin treatment decrease proliferation. (e) The ratio 
of lactate production/glucose consumption reflects rates of glycolysis, which decreases after 
treatment with BGT226 and cisplatin in SCC25 cells and after treatment with cetuximab, 
BGT226, and cisplatin in SCC61 cells. * p<0.05 rank sum test, compared with control; mean ± 
SEM. 
 
For SCC25, the free and protein-bound lifetimes of NADH and FAD (τ1 and τ2, 
respectively) show no significant change with any treatment (Table 3.1a). The NADH mean 
lifetime (τm) shows no change for any treatment, and the FAD mean lifetime increases with 
cisplatin treatment (p<0.05). For SCC61, free and protein-bound NADH lifetimes show no 
significant change with cetuximab and BGT226 treatment and increase with cisplatin treatment 
(p<0.05, Table 3.1b). For SCC61, the protein-bound FAD lifetime (τ1) shows no change with any 
treatment, and the free FAD lifetime (τ2) increases with cisplatin treatment (p<0.05). The NADH 
mean lifetime (τm) increases with BGT226 and cisplatin treatment (p<0.05), and the FAD mean 
lifetime increases with cisplatin treatment (p<0.05). NADH and FAD α1 are also listed in Table 
3.1. These data suggest that NADH α1 is more sensitive to shifts due to treatment than τ1, τ2, or 
τm, and FAD α1 is more sensitive to shifts due to treatment than τ1 or τ2. The NADH and FAD 
lifetime values for the OKF6 cells are included in Table 3.1c. 
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Table 3.1. The short and long fluorescence lifetime components (τ1 and τ2, respectively), mean 
lifetime (τm), and contribution of the short lifetime component (α1) of NADH and FAD in SCC25 
(a) and SCC61 (b) after treatment with cetuximab, BGT226, or cisplatin, as well as in OKF6 (c) 
 
(a) SCC25 
  
Control Cetuximab BGT226 Cisplatin 
NADH τ1 (ps) 528 ± 29 526 ± 34 468 ± 27 569 ± 37  
 
τ2 (ps) 2899 ± 53 2889 ± 56 2726 ± 43 2955 ± 62  
 
τm (ps) 1019 ± 37 1068 ± 39 1083 ± 36 1130 ± 46 
 
α1 0.792 ± 0.006 0.769 ± 0.007 0.728 ± 0.006 * 0.757 ± 0.003 * 
FAD τ1 (ps) 426 ± 24 396 ± 20 372 ± 19 378 ± 18 
 
τ2 (ps) 2667 ± 33 2624 ± 29 2633 ± 24 2630 ± 20 
 
τm (ps) 983 ± 30 913 ± 28 959 ± 33 1059 ± 29 * 
 
α1 0.749 ± 0.003 0.746 ± 0.003 0.74 ± 0.008 0.696 ± 0.005 * 
(b) SCC61 
  
Control Cetuximab BGT226 Cisplatin 
NADH τ1 (ps) 480 ± 26 486 ± 40 460 ± 19 796 ± 54 * 
 
τ2 (ps) 2760 ± 43 2763 ± 62 2673 ± 34 3335 ± 60 * 
 
τm (ps) 968 ± 28 1064 ± 50 1083 ± 36 * 1398 ± 50 * 
 
α1 0.785 ± 0.007 0.745 ± 0.012 * 0.728 ± 0.006 * 0.752 ± 0.007 * 
FAD τ1 (ps) 432 ± 25 363 ± 12 381 ± 20 450 ± 23 
 
τ2 (ps) 2654 ± 35 2546 ± 15 2667 ± 28 2713 ± 25 * 
 
τm (ps) 978 ± 31 913 ± 17 959 ± 33 1142 ± 30 * 
 
α1 0.751 ± 0.003 0.746 ± 0.003 0.74 ± 0.008 0.691 ± 0.005 * 
(c) OKF6 
    
  
Control 
   NADH τ1 (ps) 551 ± 38 
   
 
τ2 (ps) 3035 ± 61 
   
 
τm (ps) 1209 ± 42 
   
 
α1 0.731 ± 0.0039 
   FAD τ1 (ps) 455 ± 25 
   
 
τ2 (ps) 2706 ± 35 
   
 
τm (ps) 1037 ± 33 
   
 
α1 0.737 ± 0.0043 
   * p<0.05 rank sum test, compared with control; mean ± SEM. 
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3.5 Discussion 
 Optimized treatment regimens have potential to improve quality of life for HNSCC 
patients. The goal of this study is to characterize optical metabolic imaging for early assessment 
of treatment efficacy. The HNSCC cell lines SCC25 and SCC61 were treated with targeted 
therapies (cetuximab and BGT226) and chemotherapy (cisplatin) for 24 hours, and the optical 
redox ratio and fluorescence lifetimes of NADH and FAD were quantified. These molecular-
level measurements that reflect cellular metabolism could resolve anti-cancer treatment effects 
sooner than current imaging modalities, including CT, MRI, and PET. Early measurement of 
treatment efficacy could accelerate drug screening and identify optimal treatment regimens for 
individual patients, thereby improving patient outcomes.  
Isolation of NADH and FAD fluorescence emission was verified using cyanide 
perturbation (Figure 3.1). These shifts in the redox ratio and NADH and FAD lifetimes match 
published results for the MCF10A nonmalignant cell line from the breast [52][70][73][53]. 
However, these results have been previously unreported in cells from the oral cavity. Optical 
metabolic imaging distinguishes the malignant SCC25 and SCC61 cell lines from the 
nonmalignant OKF6 cell line (Figure 3.2). The increased redox ratio in HNSCC cells reflects 
increased reliance on glycolysis compared with oxidative phosphorylation, as expected in cancer 
cells (Warburg effect) [7]. This result agrees with previous findings that the redox ratio reports 
changes with malignancy [74]. The altered NADH and FAD fluorescence lifetimes reflect 
distinct signaling pathways in the HNSCC cells compared with nonmalignant cells. HNSCC 
cells exhibit modified intrinsic metabolic signaling that changes NADH binding sites [75], and 
the fluorescence lifetimes have been shown to change when NADH or FAD are bound to 
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different enzymes [45]. Previous studies have also shown that fluorescence lifetime imaging 
distinguishes normal from precancer in the DMBA-treated hamster cheek pouch model [32][33].  
 Changes in the redox ratio across treatment groups are consistent with proliferation rates 
after treatment. The redox ratio is a global measure of cellular metabolism, which drives 
proliferation. The redox ratio and proliferation ratio are unaffected by cetuximab treatment and 
show statistical differences with BGT226 and cisplatin treatment (Figure 3.5). The lack of effect 
from cetuximab treatment could be attributed to in vitro application as a single agent. In addition 
to inhibiting EGFR as a means of exerting effects, in vivo it has been shown that cetuximab 
initiates antibody-dependent cell-mediated cytotoxicity (ADCC) by binding to EGFR and 
recruiting natural killer cells and macrophages to digest the targeted cell [76]. However, immune 
cells are not present in these cell culture studies. In vivo, cetuximab treatment would be expected 
to have a greater impact on the optical redox ratio due to increased cell death through ADCC. 
This expectation is supported by our previous study, which showed more dramatic changes in 
redox ratio in vivo versus in vitro after treatment with the antibody trastuzumab [52]. 
Additionally, cetuximab is maximally effective in combination with radiotherapy and 
chemotherapy because it inhibits DNA repair mechanisms [18]. Conversely, BGT226 and 
cisplatin actively cause autophagy and cell death, respectively, in cell culture [61][77]. No 
previous literature has reported the effects of cetuximab or BGT226 on the optical redox ratio. 
Cisplatin has shown changes in the optical redox ratio in primary human foreskin keratinocytes 
[78].   
 The contribution from free NADH (NADH α1) shows shifts in protein-binding of NADH 
with BGT226 and cisplatin treatment in SCC25 and SCC61 cells as well as with cetuximab 
treatment in SCC61 cells (Figure 3.5b). The ratio of lactate production divided by glucose 
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consumption reflects amounts of terminal glycolysis compared with total glucose metabolism. In 
glycolysis, glucose is consumed and pyruvate is produced. Pyruvate is either fermented into 
lactate as a terminal stage of glycolysis or converted to acetyl-coA as fuel for the citric acid 
cycle. Cetuximab treatment does not affect glycolysis rates in SCC25, but decreases glycolysis in 
SCC61. The decrease in glycolysis and NADH α1 in SCC61 cells indicates shifts in metabolic 
pathways in response to treatment. However, proliferation is not affected by cetuximab in 
SCC61, indicating compensation by effectors downstream of EGFR. Cetuximab has been shown 
to not affect short-term cell growth in SCC25, which could explain the lack of statistical 
significance in the NADH α1 and glycolytic index [79]. BGT226 and cisplatin treatments 
decrease glycolysis in SCC25 and SCC61. The effect of cetuximab or BGT226 on SCC61 cells 
has not been cited in previous literature, and the effect of BGT226 on glycolysis has not been 
reported in any model. The measurement of glycolysis rates calculated by lactate 
production/glucose consumption is correlated with NADH α1 (0.81 Pearson’s correlation 
coefficient, p<0.05). No other measurements produced a statistically significant correlation 
coefficient with lactate production/glucose consumption or proliferation. Cisplatin treatment 
produces outliers that impacted the correlations, particularly between lactate production/glucose 
consumption and the redox ratio. Previous studies have shown a correlation between glucose 
uptake/lactate production and the optical redox ratio in breast cancer cells [52]. However, this 
correlation was determined for basal metabolic rates in cells without treatment, and cells from a 
different organ site could rely on different metabolic mechanisms. Additionally, the control 
SCC61 cells show a higher proliferation ratio than SCC25 (p<0.05) (Figure 3.5d), but no 
statistical difference in redox ratio (Figure 3.2a). This is in contrast to the similar lactate 
production/glucose consumption between the control SCC25 and SCC61. Although the trends in 
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NADH α1 and redox ratio agree with the gold standards, they are not surrogate measurements of 
proliferation or the amount of glycolysis compared with total glucose metabolism. For example, 
alternative metabolic pathways such as beta oxidation of fatty acids, the pentose phosphate 
pathway, and glutaminolysis are all captured differently by these gold standard measurements 
and our optical measurements [50][80]. The contribution from protein-bound FAD (FAD α1) is 
unaffected by cetuximab and BGT226 treatments and decreases with cisplatin treatment (Figure 
3.5c).  
 Early measures of treatment response could enable effective intervention while reducing 
the acute toxicities and serious morbidities from ineffective therapies. Molecular-level 
measurements that reflect cellular metabolism are well-suited to measure effects from cancer 
treatments that target metabolic pathways. The optical redox ratio and fluorescence lifetimes of 
NADH and FAD resolve a response after 24 hours of treatment with targeted therapies and 
chemotherapies in HNSCC cells. These results indicate that optical metabolic imaging shows 
promise to identify effective drug candidates during drug development. Additionally, applying 
optical metabolic imaging to measure treatment response early has potential to impact quality of 
life for HNSCC patients. 
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CHAPTER 4 
IN VIVO AUTOFLUORESCENCE IMAGING OF TUMOR HETEROGENEITY IN 
RESPONSE TO TREATMENT 
 
Shah AT, Diggins KE, Walsh AJ, Irish JM, Skala MC, “In Vivo Autofluorescence Imaging of 
Tumor Heterogeneity in Response to Treatment.” Neoplasia, 2015; 17(12):862-870 
 
4.1 Abstract 
Subpopulations of cells that escape anti-cancer treatment can cause relapse in cancer 
patients. Therefore, measurements of cellular-level tumor heterogeneity could enable improved 
anti-cancer treatment regimens. Cancer exhibits altered cellular metabolism, which affects the 
autofluorescence of metabolic cofactors NAD(P)H and FAD. The optical redox ratio 
(fluorescence intensity of NAD(P)H divided by FAD) reflects global cellular metabolism. The 
fluorescence lifetime (amount of time a fluorophore is in the excited state) is sensitive to 
microenvironment, particularly protein-binding. High-resolution imaging of the optical redox 
ratio and fluorescence lifetimes of NAD(P)H and FAD (optical metabolic imaging) enables 
single-cell analyses. In this study, mice with FaDu tumors were treated with the antibody therapy 
cetuximab or the chemotherapy cisplatin and imaged in vivo two days after treatment. Results 
indicate that fluorescence lifetimes of NAD(P)H and FAD are sensitive to early response (two 
days post-treatment, p<0.05), compared with decreases in tumor volume (nine days post-
treatment, p<0.05). Frequency histogram analysis of individual optical metabolic imaging 
parameters identifies subpopulations of cells, and a new heterogeneity index enables quantitative 
comparisons of cellular heterogeneity across treatment groups for individual variables. 
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Additionally, a dimensionality reduction technique (viSNE) enables holistic visualization of 
multivariate optical measures of cellular heterogeneity. These analyses indicate increased 
heterogeneity in the cetuximab and cisplatin treatment groups compared with the control group. 
Overall, the combination of optical metabolic imaging and cellular-level analyses provide novel, 
quantitative insights into tumor heterogeneity. 
 
4.2 Introduction 
Cancer treatments often include chemotherapy, targeted therapy, and/or radiation therapy. 
Most cancer patients respond to treatment initially, exhibiting decreased tumor volume, and later 
relapse, exhibiting increased tumor volume. Chemotherapy and targeted treatments can eliminate 
the majority of cells in a tumor while subpopulations of cells can escape treatment [54][55]. 
These subpopulations of cells may be responsible for innate or acquired resistance, which can 
enable treatment failure, disease progression, and diminished patient outcomes.  
 Standard chemotherapies and radiation treatments are administered based on average 
response rates for a particular type and stage of cancer. Current methods for determining targeted 
treatment strategies rely on identifying the dominant subpopulation of cells, usually based on 
surface marker expression, and administering drugs that inhibit the overexpressed targets to 
decrease proliferation or increase death of the cells expressing those targets [57]. Resistant 
subpopulations existing within a tumor could escape the treatment, allowing relapse after 
therapy. Therefore, tumor heterogeneity poses a difficult challenge for optimizing treatment 
outcomes in cancer patients.  
Tumor heterogeneity can be characterized as genetic, phenotypic, or functional [81][82]. 
Genetic measures focus on analysis of genes known to promote tumor progression. Phenotypic 
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characterization is usually established from histology to visualize cell morphology and from 
immunohistochemistry to measure expression of cell surface receptors, growth factors, and 
hormone receptors. However, these measures may not directly relate to cellular function [81]. 
Whereas genetic and phenotypic biomarkers provide static measurements, functional measures 
characterize dynamic tumor behavior or response to stimuli and therefore may be more 
attractive. Functional measures include cellular metabolism, oxygen consumption, and blood 
perfusion. In particular, cellular metabolism, which is altered in cancer [7], has been shown to be 
a good indicator of drug response and therefore may be a promising marker for tumor 
heterogeneity [62]. 
 Numerous metabolic pathways involve the autofluorescent co-enzymes NAD(P)H (an 
electron donor) and FAD (an electron acceptor). The optical redox ratio is defined as the 
fluorescence intensity of NAD(P)H divided by that of FAD, and is an established method for 
monitoring relative amounts of electron donor and acceptor in a cell [46][51][52]. As a 
complementary measure, the fluorescence lifetime reports the amount of time a fluorophore is in 
the excited state before relaxing to the ground the state. Fluorescence lifetime is sensitive to 
conformational changes in enzyme structure that are caused by the microenvironment, 
particularly protein-binding [39]. The fluorescence lifetime of NAD(P)H has two distinct 
components, due to vastly different lifetimes when NAD(P)H is in the free and protein-bound 
states [45]. Similarly, FAD has two lifetimes due to its free and protein-bound states [83]. The 
short lifetimes of NAD(P)H (free state) and FAD (protein-bound state) are due to quenching by 
the adenine moiety of the molecule [39]. The redox ratio and fluorescence lifetime provide 
independent measurements of cellular metabolism [52], and can be performed using two-photon 
fluorescence microscopy, which enables cellular-level imaging and deeper penetration in tissue 
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than single-photon (e.g. confocal) microscopy [84]. This approach exploits the endogenous 
contrast of NAD(P)H and FAD autofluorescence to acquire quantitative measurements of 
cellular metabolism that can be used to characterize cellular heterogeneity.  
There are few analysis approaches that are appropriate for quantifying cellular 
heterogeneity. The Shannon diversity index is a metric used in ecology literature that 
incorporates the number and relative proportions of species in a community [85], and it has also 
been applied to tumor heterogeneity [86][87][88]. However, the degree of separation between 
subpopulations is also an important consideration in tumor heterogeneity [89], which is not 
incorporated into the Shannon diversity index. A metric incorporating the number of cellular 
subpopulations, relative contributions of each subpopulation, and relative differences in 
subpopulations to quantify tumor heterogeneity could provide insight into optimal treatment 
strategies for cancer patients. This type of metric could be applied to each optical metabolic 
imaging parameter, including the redox ratio and fluorescence lifetime components of NAD(P)H 
and FAD.  
Since optical metabolic imaging acquires multi-dimensional data sets of parameters, 
which can be difficult to interpret holistically, dimensionality reduction techniques can be 
applied as a complementary method to facilitate interpretation of these types of data sets. 
Traditional methods apply a linear transformation of the data, like principal component analysis 
(PCA) [90]. However, an alternative method that preserves nonlinear relationships at a single-
cell level may be advantageous, like the viSNE technique [91]. ViSNE is a dimensionality 
reduction tool that uses t-distributed stochastic neighbor embedding (t-SNE) to plot high-
dimensional single-cell data on a two-dimensional axis for visualization of cellular 
heterogeneity, and is well-suited for single-cell data acquired in optical metabolic imaging. 
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ViSNE is also attractive for identifying cell sub-populations because it preserves the relative 
distances between cells that are present in multi-dimensional space when projecting them into 
two-dimensional space, thereby maintaining relationships between individual cells in the reduced 
data set and identifying relationships that would not be apparent by manual analysis alone. 
 This study quantifies the optical redox ratio and fluorescence lifetimes of NAD(P)H and 
FAD in a xenograft model of head and neck cancer two days after treatment with the antibody 
therapy cetuximab or the chemotherapy cisplatin. Additionally, these in vivo high-resolution 
images enabled analysis of cellular metabolic heterogeneity in response to treatment at an early 
time point using endogenous contrast. An index to quantify heterogeneity was developed, 
validated on samples containing cultures of one cell line or co-cultures containing two cell lines, 
and applied in vivo to each individual optical metabolic imaging variable. Additionally, a 
dimensionality reduction technique (viSNE) was applied to enable holistic visualization of 
heterogeneity across all optical metabolic imaging variables combined. Immunohistochemistry 
stains for cell proliferation and cell death validated treatment efficacy, and tumor growth curves 
measured gold standard treatment response. Results indicate that in vivo optical metabolic 
imaging, combined with a quantitative metric of heterogeneity or a dimensionality reduction 
visualization of heterogeneity, has potential to resolve treatment-induced cellular-level 
heterogeneities in tumors. Ultimately, characterization of cellular heterogeneity could enable 
optimized treatment regimens and improved patient outcomes.  
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4.3 Materials and Methods 
In Vivo Imaging and Tumor Growth Curves 
FaDu cells were grown in DMEM media supplemented with 10% fetal bovine serum (FBS) and 
0.4µg/mL hydrocortisone. Approximately 10
7
 FaDu cells were injected into the flanks of 7 week 
old male nude mice and tumors were grown to approximately 100mm
3
. Mice in treated groups 
received treatment of cetuximab (33mg/kg) [92][93] or cisplatin (6mg/kg) [94] via 
intraperitoneal injection. To measure tumor growth curves, mice were treated three times a week 
for two weeks (6 tumors per group). Tumor volumes were measured daily and calculated by 
(l*w
2
)/2, where l represents the tumor length in mm and w represents the tumor width in mm. 
Tumor volumes were normalized to the size on day 1. On day 13, tumors were excised and fixed 
for immunohistochemistry, and mice were euthanized. A separate cohort of mice were used for 
in vivo imaging studies, with only one dose per treatment group on day zero (6 tumors for control 
group, 5 tumors for cetuximab and cisplatin groups). Two days after treatment, each mouse was 
anesthetized and the skin covering the tumor was removed. A coverslip was placed over the 
exposed tumor, and the mouse was placed on the microscope to acquire in vivo images (3-7 
images per tumor).  
 
Imaging Instrumentation 
Mice were imaged on a custom-built (Bruker) inverted two-photon fluorescence microscope (Ti-
E Nikon) using a 40x oil immersion objective (1.3 NA). A titanium:sapphire laser (Chameleon, 
Coherent Inc.) was used for excitation, and a GaAsP photomultiplier tube (H7422P-40, 
Hamamatsu) was used for fluorescence collection. To measure NAD(P)H autofluorescence, an 
excitation wavelength of 750nm and an emission filter of 400-480nm was used. To measure 
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FAD autofluorescence, an excitation wavelength of 890nm and an emission filter of 500-600nm 
was used. Time correlated single photon counting electronics (SPC-150, Becker and Hickl) were 
used to acquire fluorescence lifetime images over 60 seconds, and photon count rates (~2-3 x 
10
5
) were monitored during this time to ensure the absence of photobleaching. A pixel dwell 
time of 4.8 μs was used to acquire 256x256 pixel images. First, an NAD(P)H lifetime image was 
acquired, and then an FAD lifetime image was acquired from the same field of view. Sequential 
fields of view were separated by at least one field of view. A Fluoresbrite YG microsphere 
(Polysciences Inc.) was imaged as a daily standard with a fluorescence lifetime of 2.11±0.05 ns 
(n=7), consistent with previous studies [32][95]. Instantaneous scattering from second harmonic 
generation of urea crystals excited at 900nm was measured to calculate the full width at half 
maximum of the instrument response function (244ps).  
 
Image Analysis 
Fluorescence lifetime images were analyzed as described previously [96]. Briefly, the 
fluorescence lifetime decay curves were fit to a two-component exponential function, F(t) = α1e
-
t/τ1+ α2e
-t/ τ2+c, where F(t) represents the fluorescence intensity over time, α1 and α2 represent the 
contribution from the short and long lifetime components respectively (α1+α2=1), and τ1 and τ2 
represents the fluorescence lifetime of the short and long lifetime components respectively 
(SPCImage, Becker and Hickl). A two-component fit has been shown to be appropriate for 
describing freely diffusing versus protein-bound conformations of NAD(P)H and FAD [32]. For 
NAD(P)H, the short lifetime represents free NAD(P)H, and for FAD the short lifetime represents 
protein-bound FAD [39]. The weighted mean lifetime, τm, was calculated by τm=α1τ1+α2τ2. A 
fluorescence intensity image was generated by integrating the fluorescence lifetime decay over 
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time for each pixel in the lifetime image. The optical redox ratio was calculated by dividing the 
NAD(P)H fluorescence intensity by the FAD fluorescence intensity for each pixel to create a 
redox ratio image for each field of view. NAD(P)H and FAD fluorescence specific to cellular 
metabolism is localized in the cytoplasm and mitochondria. Therefore, the redox ratio and 
fluorescence lifetime images were thresholded to remove nuclear fluorescence, and the average 
redox ratio and fluorescence lifetime decay parameters for each remaining cell cytoplasm was 
computed. The optical redox ratio and NAD(P)H and FAD fluorescence lifetime images were 
quantified for each cytoplasm in each cell using a customized CellProfiler routine as described 
previously [97].  
 
Heterogeneity Index and Validation 
For subpopulation analysis, frequency histograms were plotted for the optical redox ratio, 
NAD(P)H τm, and FAD τm, as described and validated in [98]. The histograms were fit to one-, 
two-, or three-component Gaussian curves, and the lowest Akaike Information Criterion 
indicated optimal fitting [8]. Each Gaussian curve represents a subpopulation of cells, and the 
sum of the Gaussian curves was plotted for visualization. To quantify heterogeneity, a 
heterogeneity index was defined as H = − ∑ 𝑑𝑖𝑝𝑖 ln 𝑝𝑖, where i represents each subpopulation, d 
represents the distance between the median of the subpopulation and the median of all data 
within a group, and p represents the proportion of the subpopulation. Validation of the 
heterogeneity index was performed on co-cultures of MDA-MB-231 and SKBr3 breast cancer 
cell lines plated at ratios of 0:100, 50:50, and 100:0. 
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ViSNE 
The viSNE dimensionality reduction tool was used to visualize cellular heterogeneity by 
incorporating all seven optical metabolic imaging parameters: the optical redox ratio, NAD(P)H 
α1, NAD(P)H τ1, NAD(P)H τ2, FAD α2, FAD τ1, and FAD τ2. The data from each parameter was 
transformed to a common scale of 0 to 100%, where 100% represented the highest value for that 
parameter across all treatment groups. Data were analyzed in Cytobank (www.cytobank.org) to 
create a viSNE map [91][99][100]. ViSNE performs t-distributed stochastic neighbor embedding 
(t-SNE) to minimize the differences between high-dimensional space and low-dimensional 
space, and produces a two-dimensional plot in arbitrary units. Briefly, a pairwise distance matrix 
is calculated in high dimensional space, which is transformed to a similarity matrix using a 
varying Gaussian kernel. The points are randomly mapped in low-dimensional space and 
iteratively rearranged to minimize the divergence between high-dimensional and low-
dimensional similarity matrices. 
 
Statistical Analyses 
Bar graphs are shown as mean ± standard error. Kruskal-Wallis and two-way rank sum tests 
determined statistical significance with an α of 0.05. 
 
4.4 Results 
Tumor growth curves measure tumor volume changes in FaDu xenografts after treatment 
(Figure 4.1a). Compared with control, cetuximab and cisplatin treatments cause tumor volume 
decreases starting six and nine days, respectively after treatment onset (p<0.05). 
Immunohistochemistry was performed on excised tumor tissue at the end of the study to quantify 
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markers of treatment efficacy (Figure 4.1). Ki-67 staining shows decreased proliferation with 
each treatment group (p<0.05; Figure 4.1b). Cleaved caspase 3 shows increased cell death with 
cisplatin treatment (p<0.05; Figure 4.1c). These gold standard measurements verify drug efficacy 
in the xenografts.  
 
Figure 4.1. In vivo validation of treatment effects. (A) Tumor growth curves show a decrease 
(*p<0.05, compared with control) in tumor volume in cetuximab treated xenografts after 6 days 
of treatment and in cisplatin treated xenografts after 9 days of treatment. Xenografts were 
excised and stained for ki-67 (proliferation) and cleaved caspase 3 (cell death) on day 13. (B) 
Xenografts from cetuximab and cisplatin treated mice exhibited decreased proliferation. (C) 
Xenografts from cisplatin treated mice exhibited increased cell death. *p<0.05 compared with 
control, rank sum test 
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Representative in vivo images demonstrate cellular-level resolution of NAD(P)H and 
FAD autofluorescence imaging and enables visualization of qualitative differences in the optical 
metabolic imaging parameters two days after treatment (Figure 4.2). Images were quantified to 
calculate the average optical redox ratio, NAD(P)H fluorescence lifetime, and FAD fluorescence 
lifetime per-cell (Figure 4.3). The redox ratio shows no change with cetuximab treatment and 
decreases with cisplatin treatment (p<0.05). The NAD(P)H fluorescence lifetime decreases with 
cetuximab  and cisplatin treatments (p<0.05). The FAD fluorescence lifetime decreases with 
cetuximab and cisplatin treatments (p<0.05). The shifts in fluorescence lifetime reflect shifts in 
microenvironment, particularly NAD(P)H and FAD protein-binding. NAD(P)H τ1, NAD(P)H τ2, 
FAD τ1, and FAD τ2 decrease with cetuximab and cisplatin treatments (Figure A.1, p<0.05). The 
relative amounts of free NAD(P)H and FAD increase and decrease, respectively, with cetuximab 
and cisplatin treatments (Figure A.1, p<0.05). 
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Figure 4.2. In vivo images of FaDu xenografts 2 days after treatment with cetuximab or cisplatin. 
NAD(P)H and FAD autofluorescence images were acquired from the same fields of view, and 
the redox ratio (top row), NAD(P)H fluorescence lifetime (middle row), and FAD fluorescence 
lifetime (bottom row) were calculated. Scale bar = 50um. 
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Figure 4.3. The optical redox ratio, NAD(P)H fluorescence lifetime, and FAD fluorescence 
lifetime quantified from in vivo NAD(P)H and FAD autofluorescence images 2 days after 
treatment. (A) The redox ratio decreases with cisplatin treatment. (B, C) The NAD(P)H and FAD 
fluorescence lifetimes decrease after cetuximab and cisplatin treatment. The shifts in NAD(P)H 
and FAD fluorescence lifetime measured 2 days after treatment are consistent with response 
measure by tumor growth curves and immunohistochemistry after 13 days of treatment. *p<0.05, 
compared with control 
 
Single-cell images were represented as histograms of number of cells versus optical 
metabolic imaging parameters, and Gaussian fits were used to identify distinct cell sub-
populations for each treatment group. Histograms plotting the sum of Gaussian fits for the redox 
ratio, NAD(P)H fluorescence lifetime, and FAD fluorescence lifetime highlight cellular 
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heterogeneity across treatment groups for each optical parameter (Figure 4.4a-c and Figure A.2). 
For the redox ratio, histograms of the treatment groups have some overlap with control. This 
trend is consistent with the NAD(P)H and FAD fluorescence lifetimes. The degree of overlap for 
the subpopulations of cells from each treatment group compared with control could reflect the 
degree of resistant cells compared with responsive cells.  
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Figure 4.4. In vivo heterogeneity analysis after treatment. To quantify the level of cellular 
metabolic heterogeneity within a treatment group, each group is fit to one, two, or three Gaussian 
curves based on the Akaike Information Criterion. Each Gaussian curve represents one 
subpopulation, and the sum of the Gaussian curves is plotted for visualization. The heterogeneity 
index, H, is a weighted sum over each subpopulation within a treatment group that incorporates 
55 
 
d, the distance between the median of the subpopulation and the median of all data in the 
treatment group, and p, the weight of the subpopulation. This parameter is the Shannon diversity 
index modified to incorporate the relative location of each subpopulation. Increased 
heterogeneity index indicates increased number of subpopulations, increased equality in the 
weights of each subpopulation within a treatment group, and increased separation in the locations 
of the subpopulations. (A) The heterogeneity index for the redox ratio is lowest for the control 
group followed by the cisplatin and cetuximab treatment groups. (B) The heterogeneity index for 
the NAD(P)H fluorescence lifetime is lowest for the control group followed by the cetuximab 
and cisplatin treatment groups. (C) The heterogeneity index for the FAD fluorescence lifetime is 
lowest for the control group followed by the cisplatin and cetuximab treatment groups. 
 
In order to compare cellular-level heterogeneity across treatment groups, a quantitative 
metric called the “heterogeneity index” was developed, validated in vitro, and then applied to in 
vivo histograms. The heterogeneity index is the Shannon diversity index weighted by a distance 
factor, where a larger value indicates more subpopulations, similar numbers of cells within each 
subpopulation, and/or more distance between subpopulations. The heterogeneity index was 
validated on co-cultures of MDA-MB-231 and SKBr3 breast cancer cell lines because they 
exhibit distinct optical redox ratios [52]. The heterogeneity index was calculated for the optical 
redox ratio of dishes including 100% MDA-MB-231 cells, 100% SKBr3 cells, and 50% MDA-
MB-231 + 50% SKBr3 cells. The condition with two cell lines causes an increased heterogeneity 
index (0.285) compared with the MDA-MB-231 cell line (0.006) or the SKBr3 cell line (0.152) 
cultured alone (Table 4.1), indicating that the heterogeneity index behaves as expected. SKBr3 
cells have been shown to exhibit intrinsic heterogeneity within the cell line based on HER2 
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expression, which could account for the relatively high heterogeneity index within that cell line 
[101]. For the in vivo studies, the heterogeneity index is increased for the treated groups 
compared with the control for the redox ratio (Figure 4.4a), NAD(P)H fluorescence lifetime 
(Figure 4.4b), and FAD fluorescence lifetime (Figure 4.4c). This trend in heterogeneity index is 
consistent for the redox ratio of FaDu cell monolayers treated with cetuximab and cisplatin in 
vitro (Figure A.4). Note that the heterogeneity index is not normalized, and therefore not 
comparable between variables.  
 
Table 4.1: Validation of the heterogeneity index. The heterogeneity index is defined as H = -
∑[dipiln(pi)], where i represents each subpopulation, d represents the distance between the 
median of the subpopulation and the median of all data within a group, and p represents the 
proportion of the subpopulation. The heterogeneity index was validated using redox ratio 
measurements of MDA-MB-231 and SKBr3 cell monolayer cultures plated at ratios of 0:100, 
50:50, and 100:0, and exhibits an increased value for the 50:50 condition. 
 
 
 
The heterogeneity index is helpful to analyze individual variables, but a dimensionality 
reduction technique is necessary to visualize tumor heterogeneity with respect to all optical 
variables combined. ViSNE reduces seven optical metabolic imaging parameters by preserving 
the similarities across cells and projecting these onto a two-dimensional axis (Figure 4.5). 
ViSNE analysis shows a distinct population of the control group, while the cetuximab and 
cisplatin treatment groups overlap with control and also exhibit a separate subpopulation of cells 
 
    
MDA-MB-231: SKBr3 Ratio 0:100 50:50 100:0 
Heterogeneity Index 0.152 0.285 0.006 
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(Figure 4.5a). This trend is consistent in FaDu cell monolayers in vitro (Figure A.4). ViSNE 
preserves similarities across cells in a nonlinear way by producing a visual two-dimensional 
scatter plot, but does not provide a quantitative relationship between the input parameters and the 
viSNE plot. Therefore, heat maps plotting the values for individual parameters over the two-
dimensional viSNE axes can be helpful for understanding the contribution of each parameter to 
the viSNE plot (Figure 4.5b-c and Figure A.3). Gradients within a parameter that correspond 
with the grouping in the viSNE plot indicate that these parameters contribute significantly to the 
viSNE plot. In particular, gradients in NAD(P)H τ1 and FAD τ1  agree with grouping in the 
viSNE plot because points in the top group of the viSNE plot exhibit low values compared with 
points in the bottom group (Figure 4.5b-c).  
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Figure 4.5. Single-cell analysis using the dimensionality-reduction technique viSNE reduces 
seven optical metabolic imaging parameters to two dimensions for visualization of heterogeneity 
across individual cells. To account for different scales between parameters, common linear 
transformation was applied within each parameter across all treatment groups so the transformed 
values range from 0 to 100. (A) ViSNE analysis shows a distinct population of cells for the 
control group. The cetuximab and cisplatin treatment groups overlap with the control group and 
also exhibit a separate subpopulation of cells. (B, C) Heat maps of the short fluorescence lifetime 
components for (B) NAD(P)H and (C) FAD show gradients over the 2-dimensional viSNE axes.  
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4.5 Discussion 
 Tumor heterogeneity poses a difficult challenge for improving treatment outcomes in 
cancer patients. The goal of this study is to apply autofluorescence imaging of the metabolic 
cofactors NAD(P)H and FAD to resolve anti-cancer treatment response on a cellular level, and 
characterize cellular heterogeneity. Mice with FaDu xenografts were treated with cetuximab or 
cisplatin, and 48 hours later the xenografts were imaged in vivo using two-photon microscopy 
and fluorescence lifetime imaging. Cellular-level imaging enabled per-cell analysis of the optical 
redox ratio and fluorescence lifetimes of NAD(P)H and FAD in response to treatment, and a 
heterogeneity index was devised to quantify cellular heterogeneity for each optical metabolic 
imaging variable. Furthermore, a dimensionality reduction technique was applied on a per-cell 
level to visualize heterogeneity on a two-dimensional axis based on combined information from 
all optical variables. Overall, the degree of heterogeneity is increased for the xenografts of mice 
treated with cetuximab or cisplatin compared with control. These nondestructive, quantitative 
methods to measure in vivo cellular heterogeneity could be used to develop improved treatments 
that account for tumor heterogeneity and target all tumor cell sub-populations for improved 
efficacy in cancer patients. 
Tumor growth curves show that over two weeks of treatment the administration of 
cetuximab or cisplatin causes stable disease, exhibiting decreased tumor volume compared with 
control tumors that exhibit continued increase in tumor volume (Figure 4.1A). These results 
agree with clinical studies of patients administered cetuximab or cisplatin [102][103]. 
Additionally, cetuximab and cisplatin treatment cause decreased cell proliferation (Figure 4.1B), 
which agrees with previous in vitro studies [104][105]. Cisplatin treatment causes increased cell 
death (Figure 4.1C). Cisplatin has been shown to cause apoptosis [106], and cetuximab sensitizes 
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cells to chemotherapy by inhibiting DNA repair mechanisms [18]. Cetuximab has been shown to 
cause autophagy instead of apoptosis [104]. These immunohistochemistry measures verify in 
vivo drug efficacy. 
 The redox ratio of FaDu xenografts measured in vivo decreases 48 hours after cisplatin 
treatment, whereas cetuximab treatment causes no change in the redox ratio (Figure 4.3A). These 
results agree with in vitro optical redox ratio measurements in SCC25 and SCC61 head and neck 
cancer cell lines treated with cetuximab or cisplatin [96]. The lack of effect from cetuximab 
treatment could reflect its administration as a single agent, since cetuximab is maximally 
effective in combination with chemotherapy and radiation therapy. Additionally, cetuximab 
initiates antibody-dependent cell cytotoxicity (ADCC), but this process might be altered in the 
immunocompromised nude mice used in this study [76]. The NAD(P)H and FAD mean lifetimes 
decrease with cetuximab and cisplatin treatment (Figure 4.3B, C), which could reflect treatment-
induced changes in preferred metabolic pathways involving NAD(P)H and FAD. These results 
also highlight the fact that the redox ratio and fluorescence lifetimes of NAD(P)H and FAD 
probe different features of cellular metabolism [52]. The redox ratio reflects relative amounts of 
electron donor (NAD(P)H) and acceptor (FAD), whereas the fluorescence lifetimes of NAD(P)H 
and FAD reflect enzyme activity, preferred protein-binding, and other microenvironmental 
factors (e.g. pH) of these co-factors [39]. Decreased NAD(P)H and FAD mean fluorescence 
lifetimes have also been measured in BT474 breast cancer xenografts treated with antibody 
therapy trastuzumab two days after treatment [52]. No previous literature has reported the effects 
of chemotherapy in vivo on the optical redox ratio and fluorescence lifetimes of NAD(P)H and 
FAD. These fluorescence lifetime changes two days after treatment agree with tumor volume 
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decreases in treated mice nine days after treatment onset, indicating that NAD(P)H and FAD 
fluorescence lifetime measurements could reflect early treatment-induced metabolic effects.  
 To visualize treatment-induced shifts in cellular heterogeneity, frequency histograms 
were plotted for the optical redox ratio and mean fluorescence lifetimes of NAD(P)H and FAD. 
Shifts in the histograms can be qualitatively visualized across control and treatment groups 
(Figure 4.4), and a metric to describe cellular heterogeneity is necessary for quantitative 
comparisons. However, there is no standard metric for quantifying tumor heterogeneity. We have 
modified the Shannon diversity index to incorporate the relative separation between 
subpopulations by including a coefficient of the distance between the median of each 
subpopulation to the median of the group. Since the scale and range of this coefficient depends 
on the parameter, the heterogeneity index is a relative value for each parameter. A heterogeneity 
index of 0 indicates one population of cells, and the index increases with increased number of 
subpopulations, evenness between subpopulations, and distance between subpopulations. The 
heterogeneity index increases for co-cultures of SKBr3 and MDA-MB-231 cells compared with 
either cell line alone (Table 4.1), indicating that an increased heterogeneity index reflects 
increased sample heterogeneity. The heterogeneity index was calculated for the redox ratio, 
NAD(P)H fluorescence lifetime, and FAD fluorescence lifetime (Figure 4.4), and is consistently 
lower for the control group compared with the cetuximab or cisplatin treatments. The higher 
heterogeneity index for the treatments indicates increased variability in cellular response to each 
treatment, and could indicate a balance between cellular response and resistance that leads to 
stable disease as seen in tumor growth curves (Figure 4.1A). Additionally, in vitro heterogeneity 
analysis of FaDu cell monolayers show similar response as in vivo results, indicating intrinsic 
heterogeneity in the FaDu cell response to cetuximab and cisplatin (Figure A.4). Other factors 
62 
 
could also contribute to in vivo drug response, including hypoxia, drug delivery, and glucose 
gradients. These factors could induce greater heterogeneity in the in vivo optical metabolic 
imaging measurements compared to in vitro measurements. 
The heterogeneity index can be applied to individual optical metabolic imaging 
parameters. However, since the seven optical metabolic imaging parameters are complementary 
measures [52], incorporating all parameters into one heterogeneity analysis could provide 
additional insight for characterizing tumor heterogeneity. Dimensionality reduction techniques 
can preserve the similarity between cells across multiple variables, and project relative distances 
between cells onto a two-dimensional scatter plot. Common dimensionality reduction techniques 
include principal component analysis (PCA), but this method requires a linear transformation of 
the data [107]. The viSNE technique optimizes the separation between cells based on high-
dimensional data sets without relying on a linear transformation of the data, so it can preserve 
non-linear relationships at single-cell resolution, identify rare subpopulations of cells, and 
provide a two-dimensional plot for visualization of cellular heterogeneity [91]. These advantages 
make viSNE an attractive tool for the analysis of optical metabolic imaging parameters. ViSNE 
analysis shows a distinct population of cells in the control group. In contrast, the cetuximab and 
cisplatin treatment groups overlap with control and also display a separate subpopulation of cells 
(Figure 4.5). This indicates increased heterogeneity in the treatments compared with the control, 
which agrees with the analysis of the heterogeneity index applied to individual optical metabolic 
imaging parameters (redox ratio, NAD(P)H and FAD fluorescence lifetimes). A gradient in the 
short lifetime components of NAD(P)H and FAD can be seen across the viSNE map (Figure 
4.5B, C), which indicates that these optical parameters contribute more variability to the data set. 
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These results indicate that the combination of optical metabolic imaging and single-cell analyses 
(heterogeneity index, viSNE) are attractive for characterizing tumor heterogeneity. 
 Tumor heterogeneity poses a challenge for optimizing anti-cancer treatment strategies in 
cancer patients, and new tools are necessary to adequately quantify and interpret tumor 
heterogeneity in vivo in animal models at a cellular level. This study shows that optical metabolic 
imaging can resolve metabolic shifts induced by chemotherapy and targeted therapy in vivo at an 
early time point. Autofluorescence imaging on a cellular level is well-suited for analysis of 
heterogeneity across single cells. In particular, a heterogeneity index can quantify drug-induced 
shifts in heterogeneity across treatment groups for individual variables, and dimensionality 
reduction techniques can be advantageous for holistic interpretation of multivariate measures of 
cellular heterogeneity. These methods for assessing tumor heterogeneity could enable improved 
treatment regimens that account for tumor heterogeneity, leading to improved outcomes for 
cancer patients. 
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CHAPTER 5 
EX VIVO LABEL-FREE MICROSCOPY OF HEAD AND NECK CANCER PATIENT 
TISSUES  
 
Shah AT, Skala MC, “Ex Vivo Label-Free Microscopy of Head and Neck Cancer Patient 
Tissues.” SPIE Proceedings, 2015; 9329 
 
5.1 Abstract 
Standard methods to characterize patient tissue rely on histology. This technique provides 
only anatomical information, so complementary imaging methods could provide beneficial 
phenotypic information. Cancer cells exhibit altered metabolism, and metabolic imaging could 
be applied to better understand cancer tissue. This study applies redox ratio, fluorescence 
lifetime, and second harmonic generation (SHG) imaging to ex vivo tissue from head and neck 
cancer patients. This high-resolution imaging technique has unique advantages of utilizing 
intrinsic tissue contrast, which eliminates the need for sample processing or staining, and 
multiphoton microscopy, which provides depth sectioning in intact tissue. This study 
demonstrates feasibility of these measurements in patient tissue from multiple anatomical sites 
and carcinoma types of head and neck cancer. 
 
5.2 Introduction 
Head and neck cancer is a complex disease encompassing several anatomical sites 
including the oral cavity, pharynx, larynx, salivary glands, and thyroid[108]. Current methods to 
characterize malignant and benign patient tissue rely on histology, which requires tissue to be 
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fixed, sectioned, and stained for visualizing the anatomy of cells. Histology can be difficult to 
interpret because it lacks functional information to explain the causes of tissue morphology. 
Therefore, additional imaging methods could provide complementary phenotypic information for 
characterizing tissue samples. In particular, cancer cells exhibit altered metabolism, which can 
drive changes in cell morphology, cell proliferation, and cell death[7][109]. 
Cellular metabolism can be investigated using autofluorescence of nicotinamide adenine 
dinucleotide (NADH) and flavin adenine dinucleotide (FAD), which are involved in glycolysis 
and oxidative phosphorylation. The optical redox ratio is calculated by dividing the fluorescence 
intensity of NADH by that of FAD and provides a measure of global metabolism[46]
,
[52]
,
[51]. 
The fluorescence lifetime is the time a fluorophore is in the excited state before relaxing to the 
ground state and is influenced by fluorophore microenvironment, particularly protein-
binding[39]. These techniques combined with multiphoton fluorescence microscopy provide 
micron-level resolution imaging. Additionally, this setup enables imaging of second harmonic 
generation (SHG), a nonlinear optical process produced by highly ordered proteins like collagen, 
which are important in tumor microenvironments[110]. These imaging methods utilize intrinsic 
tissue contrast, which eliminates cost and time for tissue processing that is required in histology.  
Furthermore, multiphoton microscopy enables depth sectioning in intact tissue and could allow 
three-dimensional reconstruction[42]. This microscopy technique combines redox ratio imaging, 
fluorescence lifetime imaging of NADH and FAD, and collagen SHG imaging to provide 
metabolic and structural information valuable for understanding samples of human tissue. 
Previous studies have applied autofluorescence imaging to human head and neck cancer 
cells and tissue. In cultures of oral cavity cells in vitro, autofluorescence intensity and lifetime 
imaging of NADH and FAD have been shown to distinguish malignant from nonmalignant 
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human cell lines[96]. Studies in human tissue focus on fluorescence intensity imaging. In 
particular, patient samples from normal, malignant, and inflammatory tissue of the oral cavity 
have been characterized using confocal microscopy[111]. Additionally, in vivo autofluorescence 
imaging and spectroscopy for head and neck cancer have used fiber optic probes to diagnose 
malignant tissue[112]
,
[113]. Complementing fluorescence intensity with fluorescence lifetime 
and SHG imaging could provide valuable contrast without requiring additional processing of the 
tissue sample.  
The goal of this study is to apply redox ratio, fluorescence lifetime, and SHG imaging to 
acquire functional and structural images of ex vivo human tissue from head and neck cancer 
patients. Tissue samples were collected from multiple types of head and neck cancer, and images 
were acquired. These results establish feasibility of these measurements in human head and neck 
cancer tissue. Overall, this metabolic imaging technique could serve as a valuable method to 
acquire phenotypic information from intact tissue as a complementary method to histology. 
 
5.3 Methods 
Tissue Sample Collection 
An institutional review board (IRB) exemption letter was obtained and de-identified human 
tissue samples were collected using the Cooperative Human Tissue Network (CHTN) at 
Vanderbilt University. After excision, tissue was placed in Dulbecco’s Modified Eagle Medium 
(DMEM) cell culture media supplemented with 10% fetal bovine serum (FBS) and 0.4µg/mL 
hydrocortisone and kept on ice. Tissue was moved to a glass-bottomed petri dish (MatTek) for 
image acquisition. 
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Image Acquisition 
An inverted multiphoton microscope and time correlated single photon counting (TCSPC) 
electronics were used to collect fluorescence intensity and lifetime images, as described 
previously[96]. Briefly, a titanium:sapphire laser was used for excitation and a photomultiplier 
tube was used for collection. NADH signal was isolated using an excitation wavelength of 
750nm and a bandpass emission filter of 440/80nm. FAD signal was isolated using an excitation 
wavelength of 890nm and a bandpass emission filter of 550/100nm. SHG signal was isolated 
using an excitation wavelength of 890nm and a bandpass emission filter of 450/35nm. NADH 
autofluorescence, FAD autofluorescence, and SHG images were acquired from the same fields of 
view. Intensity images were averaged over 4 frames to improve signal to noise. Fluorescence 
lifetime images were acquired over 60 seconds.  
 
Image Analysis 
An NADH intensity image was divided by a FAD intensity image from the same field of view to 
calculate a redox ratio image (ImageJ). The fluorescence lifetime was calculated by 
deconvolving the instrument response function with the fluorescence lifetime decay and fitting to 
a two-component curve, as described previously[96]. The average fluorescence lifetime, τm, was 
calculated by τm=α1τ1 + α2τ2, where α is the contribution from each component and τ is the 
lifetime of each component. 
 
5.4 Results 
Patient tissue of malignant tongue was collected and imaged (Figure 5.1). Hematoxylin 
and eosin (H&E) stain shows tightly packed cells and verifies malignant status of the tissue. 
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Representative redox ratio, NADH lifetime, and FAD lifetime images highlight morphology of 
tumor cells, particularly the cell cytoplasm that emanates NADH and FAD autofluorescence.  
Squamous cell carcinoma (SCC) tissue of the tongue and matched normal tissue of the 
tongue were collected from the same patient and imaged (Figure 5.2). The SCC tissue shows 
cells with nuclei compared with the normal tissue that shows vesicles resembling adipocytes 
with higher redox ratios. Additionally, the SCC tissue exhibits lower NADH and FAD 
fluorescence lifetimes than the normal tissue. SHG from collagen is arranged in the extracellular 
matrix surrounding cells. 
 
Figure 5.1. Representative hematoxylin and eosin (H&E) histology stain (60x60µm image size), 
redox ratio, NADH lifetime, and FAD lifetime images (170x170µm image size) from malignant 
tongue. 
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Samples were acquired from patients with adenocarcinoma of the parotid salivary gland 
and SCC of the parotid salivary gland (Figure 5.3). The adenocarcinoma tissue shows higher 
redox ratios and lower NADH and FAD fluorescence lifetimes than the SCC tissue. The 
adenocarcinoma sample shows more collagen than the SCC sample. One sample was acquired 
from a patient with laryngeal cancer (Figure 5.4), and microscopy images show larger cells 
compared with the other carcinoma samples.  
 
Figure 5.2. Representative images from squamous cell carcinoma of the tongue (top row) and 
normal tissue (bottom row) from the same patient. Images are 170x170µm. 
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Figure 5.3. Representative images from adenocarcinoma (top row) and squamous cell carcinoma 
(bottom row) from the parotid salivary gland. Images are 170x170µm. 
 
Figure 5.4. Representative images from patient tissue of laryngeal cancer. Images are 
170x170µm. 
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5.5 Discussion 
The goal of this study is to establish feasibility of applying redox ratio, fluorescence 
lifetime, and SHG imaging to human tissue samples of head and neck cancer. Patient tissues 
from multiple anatomical sites were imaged, including the tongue, parotid salivary gland, and 
larynx. Additionally, a matched normal sample from a patient with SCC of the tongue was 
obtained. Autofluorescence images from normal tissue and SCC tissue show cell morphology 
and different cell types, particularly fat vesicles in the normal tissue versus tumor cells in the 
SCC tissue. The normal and SCC tissue exhibit distinct fluorescence lifetimes of NADH and 
FAD, which reflects differences in protein-binding involving NADH and FAD for each sample 
(Figure 5.2). Head and neck cancer can also include multiple cell types of origin. For example, 
adenocarcinoma originates from glandular cells whereas SCC originates from squamous cells. 
Adenocarcinoma tissue of the parotid salivary gland shows higher optical redox ratios than SCC, 
reflecting higher rates of glycolysis compared with oxidative phosphorylation (Figure 5.3). 
Differences in NADH and FAD fluorescence lifetime between the adenocarcinoma and SCC 
reflect different metabolic pathways utilized for each tissue type. These functional measurements 
could help influence treatment strategies because anti-cancer treatment often impacts cellular 
metabolism. Since tumor cells exhibit increased NADH autofluorescence in the cytoplasm 
compared with the nuclei, NADH autofluorescence images can provide visualization of cellular 
and nuclear size. Autofluorescence imaging of laryngeal cancer shows increased cellular and 
nuclear size compared with SCC of the tongue, SCC of the parotid salivary gland, and 
adenocarcinoma of the parotid salivary gland. Overall, high-resolution functional imaging of 
human tissue could serve as a method to characterize tissue phenotype and provide a 
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complementary imaging method to histology that does not require processing and destruction of 
the tissue samples. 
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CHAPTER 6 
METABOLIC IMAGING OF HEAD AND NECK CANCER ORGANOIDS  
 
6.1 Abstract 
Head and neck cancer patients suffer from toxicities, morbidities, and mortalities, and 
these ailments could be minimized through improved therapies. Drug discovery is a long, 
expensive, and complex process, so optimized assays can improve the success rate of drug 
candidates. This study applies optical imaging of cell metabolism to three-dimensional in vitro 
cultures of head and neck cancer grown from primary tumor tissue (organoids). This technique is 
advantageous because it measures cell metabolism using intrinsic fluorescence from NAD(P)H 
and FAD on a single cell level for a physiologically-relevant in vitro model. Head and neck 
cancer organoids are characterized alone and after treatment with standard therapies, including 
an antibody therapy, a chemotherapy, and combination therapy. Additionally, organoid cellular 
heterogeneity is analyzed quantitatively and qualitatively. Gold standard measures of treatment 
response, including cell proliferation, cell death, and tumor volume, validate therapeutic efficacy 
in each treatment group. Results indicate that optical metabolic imaging is sensitive to 
therapeutic response in organoids after 1 day of treatment (p<0.05) and resolves cell 
subpopulations with distinct metabolic phenotypes. Ultimately, this platform could provide a 
sensitive and physiologically-relevant high-throughput assay to streamline the drug discovery 
process for head and neck cancer.  
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6.2 Introduction 
Head and neck cancer describes malignant tumors in the mouth, nose, and throat. Current 
treatments include chemotherapy, surgery, radiation therapy, and targeted therapy. Despite 
advancements in therapies, the 5-year survival rate for head and neck cancer is between 40-50% 
[1]. Additionally, chemotherapy, surgery, and radiation therapy introduce major toxicities, 
including damage to tissue and organs in anatomical sites that are critical for breathing, eating, 
and talking [114]. Therefore, organ preservation is an important consideration to maintain 
normal function. Targeted treatments for head and neck cancer focus on inhibition of the 
epidermal growth factor receptor (EGFR), particularly with the anti-EGFR antibody cetuximab 
[4]. However, there is a lack of targeted therapies beyond EGFR inhibitors. Additionally, tumor 
heterogeneity can allow a minority population of cells to drive treatment resistance and tumor 
recurrence [54]. Optimized therapies could provide better treatment efficacy and reduced 
toxicities, leading to improved quality of life and longer survival, but drug development takes at 
least 10 years and more than $1 billion [115][116]. Therefore, more accurate rapid drug screens 
to identify the most promising drug candidates and combination treatments would increase the 
success rate during drug development and facilitate the commercialization of optimized drugs 
and combinations. 
In vitro three-dimensional cultures grown from primary tumor tissue (organoids) are 
attractive for a high-throughput drug screen that enables testing of multiple drugs and drug 
combinations. Cellular level measurements can identify cell subpopulations that exhibit different 
sensitivities to treatments, and organoids combined with high-resolution imaging of cell 
metabolism provides a promising platform. Organoids are physiologically relevant because they 
grow in a three-dimensional organization, are generated from tumor tissue, and can therefore 
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capture distinct behaviors of individual tumors [117]. Additionally, multiphoton microscopy of 
cell metabolism has been shown to resolve therapeutic response in cancer [52][96], and the 
spatial scales of this imaging technique allow the full volume of the organoid to be imaged on a 
single-cell level. Autofluorescence measurements of the metabolic cofactors NAD(P)H and FAD 
characterize cell metabolism using their fluorescence intensities and lifetimes [46][39]. The 
fluorescence intensity measures relative amounts of each cofactor and the optical redox ratio, 
defined as the fluorescence intensity of NAD(P)H divided by that of FAD, reflects global cell 
metabolism. The fluorescence lifetime measures the amount of time a molecule is in the excited 
state, reflects protein-binding, and is sensitive to cellular signaling pathways that use NAD(P)H 
and FAD. Metabolic imaging based on cellular autofluorescence provides early, sensitive 
measurements of anti-cancer treatment response [52]. 
Organoids have been established and characterized for some types of cancers, including 
breast cancer and pancreatic cancer [118][119]. Different anatomical sites exhibit different cell 
types, cell structures, media and growth factor requirements, matrix stiffness requirements, and 
tissue digestion protocols, so characterization of each tumor type is necessary. Previous studies 
have focused on culturing spheroids from head and neck cancer cell lines [120], organoids from 
human salivary glands [121], and tumor pieces from head and neck cancer patients [122]. 
Therefore, characterization and analysis of head and neck cancer organoids grown from primary 
tumor tissue would be a new and beneficial contribution.  
The lack of targeted treatments for head and neck cancer justify the need for a high-
throughput drug screen. This study describes properties of tumor tissue that can be used for 
growing head and neck cancer organoids, establishes a protocol for generating the organoids, and 
applies metabolic microscopy for non-invasively characterizing organoids alone and in response 
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to drug treatments. Overall, this technique could be applied to streamline drug discovery and 
enable the development of optimized therapies with high efficacy and low toxicity. 
 
6.3 Materials and Methods 
Tissue Culture and Tumor Inoculation 
FaDu cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) plus 10% fetal bovine 
serum (FBS) and 0.4 µg/mL hydrocortisone. Subcutaneous flank tumors were inoculated in nude 
mice with 10
7
 FaDu cells. Tumors were grown for 1-2 weeks until reaching a volume of 
~100mm
3
. For in vivo imaging the mouse was anesthetized, the tumor was exposed, and the 
mouse was placed on the microscope. Organoid media consisted of DMEM plus 10% FBS, 0.4 
µg/mL hydrocortisone, 1% penicillin: streptomycin, insulin-transferrin-selenium at a 1X 
concentration, 10ng/mL epidermal growth factor, and B27 at a 1X concentration. Treatment 
media for organoids included cetuximab (20nM) [104], cisplatin (33µM) [78], or their 
combination.  
 
Organoid Generation 
Mice were anesthetized and tumors were excised and immediately placed in chilled culture 
media. Tumors were washed 3 times with sterile phosphate buffered saline (PBS), transferred to 
35mm petri dishes with 0.5mL culture media, and mechanically digested with scissors. Digestion 
into a cellular suspension was confirmed with brightfield microscopy. The cell suspension was 
mixed with matrigel at a volume ratio of 1 part cell suspension to 2 parts matrigel, and 100µL 
was plated on each 35mm glass-bottomed imaging dish (MatTek). The gels solidified at room 
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temperature for 30 minutes and then at 37C for 1 hour. Then 2mL organoid media was added to 
each dish and organoids were grown at 37C.  
 
Tumor Growth Curves and Immunohistochemistry 
Mice with FaDu tumors were treated 3 times a week for 2 weeks with cetuximab (33mg/kg) 
[92][93], cisplatin (6mg/kg) [94], or their combination via intraperitoneal injection (6 tumors per 
group). Tumor volumes were measured once a day using calipers, and tumor volumes were 
calculated by (l*w
2
)/2, where l is the tumor length and w is the tumor width. Tumor volumes 
were normalized to the size on day 1. On day 11 for the combination treated mice or day 13 for 
the single agent treated mice, tumors were excised and fixed for immunohistochemistry, and the 
mice were euthanized. Weight loss in the combination treatment group required an end of the 
treatment course on day 11. 
 
Fluorescence Microscopy 
Instrumentation for fluorescence microscopy included an inverted multiphoton microscope 
(Bruker), a tunable titanium:sapphire laser (Coherent) for fluorescence excitation, and a Ga:AsP 
photomultiplier tube for collection. Time correlated single photon counting (TCSPC) electronics 
(SPC-150, Becker and Hickl) were used for fluorescence lifetime acquisition. NAD(P)H was 
imaged using an excitation wavelength of 750nm and a collection filter of 400-480nm. FAD was 
imaged using an excitation wavelength of 900nm and a collection filter of 500-600nm. 
NAD(P)H and FAD were imaged from the same fields of view. Microscopy was performed to 
collect images of 256x256 pixels using a 40X objective (1.3NA), 4.8 µsecond pixel dwell time, 
60 second collection time, and ~10mW excitation power. Photon count rates were monitored to 
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ensure the absence of photobleaching. A Fluoresbrite YG microsphere (Polysciences Inc.) was 
measured at each imaging session, and provided a lifetime of 2.10 ± 0.02 ns (n=5), which agrees 
with previous reported values [32][95]. The instrument response function (IRF) was measured 
using second harmonic generation of urea crystals resulting in a full width at half max of 244ps. 
For organoid and tumor imaging, 4-6 fields of view were acquired per group. 
 
Image Analysis 
Images were analyzed using SPCImage (Becker and Hickl), as described previously [123]. 
Spatial binning included each pixel and the surrounding 8 pixels. The fluorescence decay curves 
were de-convolved with the IRF and fit to a 2-component exponential function, F(t) = α1e
-t/τ1
 + α 
2e
-t/τ2. Here,  α represents the contribution from each component, τ represents the fluorescence 
lifetime of each component, and the 2 components reflect free and protein-bound forms of 
NAD(P)H and FAD [32]. For NAD(P)H the short lifetime reflects the freely diffusing 
conformation while the long lifetime reflects the bound conformation. Conversely, for FAD the 
short lifetime reflects the bound conformation while the long lifetime reflects the freely diffusing 
conformation [39]. The mean lifetime was calculated by τm = α1τ1+ α 2τ2. The optical redox ratio 
was calculated as the fluorescence intensity of NAD(P)H divided by the fluorescence intensity of 
FAD for each pixel. CellProfiler was applied to analyze images on a per-cell basis, as described 
previously [97]. Bar plots are consistent across 3 replicates. 
 
Heterogeneity Analysis 
Heterogeneity analysis was performed as described previously [123]. Briefly, per-cell data was 
plotted as frequency distributions and fit to 1, 2, or 3 Gaussian curves based on the Akaike 
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Information Criterion, where each Gaussian curve represented a cell subpopulation. Validation 
of this approach has shown accuracy within 10% in vitro [98]. The sum of the Gaussian curves 
was plotted. A heterogeneity index, based on a weighted Shannon diversity index, was applied to 
quantify cellular heterogeneity using the equation 𝑯 =  −∑𝒅𝒊𝒑𝒊𝒍𝒏𝒑𝒊 [123]. Here, i represents 
each subpopulation, d represents the distance between the median of the subpopulation and the 
median of all data within a group, and p represents the proportion of the subpopulation. For 
spatial mapping of cell subpopulations, thresholds between each subpopulation were calculated 
as values equidistant from the Gaussian curve means. The nucleus of each cell was color-coded 
according to these threshold values. Spatial heterogeneity analysis is shown for 1 replicate. 
 
Statistical Analysis 
Bar graphs are shown as mean ± standard error. For microscopy images statistical significance 
was determined using a Student’s t-test. For tumor growth curves and immunohistochemistry 
statistical significance was determined using a Wilcoxon rank sum test and Bonferroni 
correction. An α of 0.05 defined statistical significance. 
 
6.4 Results 
 Tumor tissue used to generate organoids was characterized with immunohistochemistry, 
histology, and autofluorescence imaging (Figure 6.1). Cleaved caspase-3 staining shows minimal 
cell death and ki-67 staining shows high cell proliferation (Figure 6.1A, B). H&E staining 
indicates tissue composition of dense tumor cells (Figure 6.1C). Cytokeratin AE1/AE3 staining 
demonstrates the epithelial status of the majority of cells (Figure 6.1D). Autofluorescence images 
show packed tumor cells with high NAD(P)H intensity localized in the cell cytoplasm and FAD 
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intensity localized in mitochondria (Figure 6.1E, F). These observations were confirmed in 
consultation with a trained pathologist. Tumor tissue was mechanically digested to break up the 
structural component and generate a suspension of single cells or small groups of cells (Figure 
6.1G), which enables organoids to grow as multi-cellular aggregates (Figure 6.1H). 
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Figure 6.1. Representative immunohistochemistry, histology, and autofluorescence images of 
tumor tissue and brightfield microscopy for organoid generation. (A) Cleaved caspase-3 staining 
shows minimal apoptosis. (B) Ki-67 staining demonstrates high cell proliferation. (C) H&E 
staining indicates tissue composition of dense tumor cells. (D) Cytokeratin AE1/AE3 indicates 
positive staining of epithelial cells, which constitute the majority of the tumor. (E) NAD(P)H 
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autofluorescence shows NAD(P)H located in the cell cytoplasm. (F) FAD autofluorescence 
shows punctate fluorescence signal from mitochondrial FAD. (G) Tissue was mechanically 
digested to create a suspension of cells. (H) Cells grow as organoids after plating the cell 
suspension. Scale bar = 50um. 
 
 Fluorescence lifetime values are robust and self-referenced, enabling comparisons across 
data sets and between tumor tissue and organoids (Figure 6.2). Organoids exhibit higher mean 
lifetimes of NAD(P)H and FAD than in vivo tumors (p<0.05), which results from lower 
contributions of the short lifetime (α1) and higher values of the short and long fluorescence 
lifetimes (τ1 and τ2) (Figure B.1). Frequency distribution modeling of the fluorescence lifetimes 
qualitatively illustrates shifts toward higher lifetimes for organoids compared with tumor tissue. 
Additionally, the heterogeneity index (H) quantifies cellular heterogeneity, where an increased 
heterogeneity index reflects increased number of cell subpopulations, increased equality in the 
weights of the subpopulations, or increased separation between the subpopulations [123]. 
Organoids exhibit similar cellular heterogeneity compared with the in vivo tumor based on the 
NAD(P)H fluorescence lifetime and increased cellular heterogeneity compared with the in vivo 
tumor based on the FAD fluorescence lifetime. 
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Figure 6.2. Untreated organoids and in vivo tumor tissue display distinct optical metabolic 
imaging properties. The weighted mean is calculated by τm= α1τ1 + α2τ2, where τ represents the 
lifetime value and α represents the contribution from each component. (A, C) Organoids exhibit 
higher NAD(P)H and FAD fluorescence lifetimes (τm) compared with in vivo tumor tissue, 
which is explained by lower contributions of the short lifetime component (α1), higher values of 
the short fluorescence lifetime (τ1), and higher values of the long fluorescence lifetime (τ2) (See 
Figure B.1). (B, D) Population distribution analysis plots cellular heterogeneity for in vivo tumor 
tissue compared with organoids. The heterogeneity index (H) is similar between organoids and in 
vivo tumor based on the NAD(P)H fluorescence lifetime and increases for organoids compared 
to in vivo tumor based on the FAD fluorescence lifetime. *p<0.05, t-test, n~100-300 cells per 
group 
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A representative autofluorescence image demonstrates the NAD(P)H fluorescence 
intensity in the organoids (Figure 6.3). In particular, organoids exhibit populations of cells with 
high NAD(P)H intensity as well as cells with low NAD(P)H intensity, and these populations 
exhibit distinct metabolic properties. Cells with low NAD(P)H exhibit a lower redox ratio and 
higher FAD fluorescence lifetime, explained by a lower contribution of the short lifetime (α1) 
(Figure B.2), compared with cells with high NAD(P)H (p<0.05).  
 
 
Figure 6.3. Untreated organoids contain cells with high levels of NAD(P)H intensity and cells 
with low levels of NAD(P)H intensity. (A) A representative image shows organoids with two 
levels of NAD(P)H intensity. (B) Low NAD(P)H cells exhibit a lower optical redox ratio than 
high NAD(P)H cells. (C) Low and High NAD(P)H cells exhibit similar NAD(P)H lifetimes. (D) 
Low NAD(P)H cells exhibit a higher FAD lifetime than high NAD(P)H cells. Scale bar = 50um. 
*p<0.05, t-test, n~50-100 cells per group 
 
 Gold standard techniques validate therapeutic efficacy and measure in vivo response to 
treatment. Immunohistochemistry characterizes short-term and long-term effects of treatment on 
cell proliferation measured by ki-67 and cell death measured by cleaved caspase 3 (Figure 6.4). 
Two days after in vivo treatment, cell proliferation is consistent across all treatment groups and 
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cell death increases with cisplatin treatment (Figure 6.4A, B). Two weeks after treatment cell 
proliferation decreases with cetuximab, cisplatin, and combination treatment and cell death 
increases with cisplatin and combination treatment  (Figure 6.4C, D) (p<0.05). Tumor growth 
curves illustrate long-term in vivo response to treatment (Figure 6.4E). Control mice exhibit 
continual tumor growth, whereas mice treated with single agents of cetuximab or cisplatin 
exhibit stable tumor volume, and mice treated with the combination of cetuximab and cisplatin 
exhibit decreased tumor volume. 
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Figure 6.4. Cell proliferation and cell death were quantified using Ki-67 and Cleaved Caspase 3, 
respectively, in FaDu xenografts after mice were treated for 2 days or 2 weeks, and tumor growth 
curves show treatment effects over 2 weeks in mice with FaDu xenografts. (A) Cell proliferation 
is consistent across treatment groups in FaDu xenografts 2 days after treatment. (B) Cell death 
increases after 2 days of treatment with cisplatin. (C) Cell proliferation decreases after 2 weeks 
of treatment with cetuximab, cisplatin, and their combination. (D) Cell death increases after 2 
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weeks of treatment with cisplatin and the combination of cetuximab and cisplatin. (E) Treatment 
with cetuximab or cisplatin causes stable disease, whereas combination treatment causes 
response.*p<0.05 compared with control, rank sum test; †p<0.05, compared with combination 
treatment, n=6 tumors 
 
 Representative images show organoid and cell morphology as well as relative trends in 
the redox ratio, NAD(P)H lifetime, and FAD lifetime for each treatment group (Figure 6.5). 
Optical metabolic imaging quantifies drug effects 1 day after treatment in organoids (Figure 6.6). 
The redox ratio increases with cetuximab and decreases with cisplatin and combination treatment 
(p<0.05). The NAD(P)H fluorescence lifetime (τm) decreases with cetuximab, cisplatin, and 
combination treatment (p<0.05). The contribution from the short lifetime (α1) increases with 
cetuximab treatment and decreases with cisplatin and combination treatment. The values of the 
short and long fluorescence lifetimes (τ1 and τ2) decrease with cetuximab, cisplatin, and 
combination treatment (Figure B.3). The FAD fluorescence lifetime (τm) increases with 
cetuximab, cisplatin, and combination treatment (p<0.05). The contribution from the short 
lifetime (α1) decreases with cetuximab, cisplatin, and combination treatment. The values of the 
short and long fluorescence lifetimes (τ1 and τ2) increase with cetuximab, cisplatin, and 
combination treatment (Figure B.3).  
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Figure 6.5. Autofluorescence images show the redox ratio and fluorescence lifetimes of 
NAD(P)H and FAD in head and neck cancer organoids treated for 1 day with cetuximab, 
cisplatin, or their combination. NAD(P)H and FAD autofluorescence images were acquired from 
the same fields of view, and the redox ratio (top row), NAD(P)H fluorescence lifetime (middle 
row), and FAD fluorescence lifetime (bottom row) were calculated. Scale bar = 50um. 
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Figure 6.6. The redox ratio and fluorescence lifetimes of NAD(P)H and FAD were quantified in 
organoids treated for 1 day with cetuximab, cisplatin, or their combination. (A) The redox ratio 
increases with cetuximab treatment and decreases with cisplatin and the combination treatment. 
(B) The NAD(P)H lifetime decreases with cetuximab, cisplatin, and combination treatment. (C) 
The FAD lifetime increases with cetuximab, cisplatin, and combination treatment. *p<0.05, t-
test; n~50-200 cells per group 
 
Cell subpopulations describe heterogeneity within treatment groups. Heterogeneity 
analysis applies Gaussian fitting of per-cell data and plots the sum of the Gaussian curves, 
illustrating shifts toward lower NAD(P)H lifetimes after cetuximab, cisplatin, and combination 
treatment (Figure 6.7). The control and combination treatment groups exhibit one subpopulation, 
whereas the cetuximab and cisplatin groups exhibit two subpopulations. For each treatment 
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group the summed area under the Gaussian curves equals one. Control and combination treated 
organoids display a low heterogeneity index, whereas single agent treated organoids display a 
higher heterogeneity index. Additionally, spatial mapping shows localization of the cell 
subpopulations. Each organoid contains one or both of the subpopulations, and qualitative 
analysis indicates that cell subpopulations are scattered throughout the organoids. 
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Figure 6.7. Cellular heterogeneity was analyzed based on NAD(P)H fluorescence lifetime in 
head and neck cancer organoids after 1 day of treatment with cetuximab, cisplatin, and their 
combination. (A) The sum of Gaussian curve fits provides qualitative visualization of cellular 
heterogeneity. A heterogeneity index (H) indicates low cellular heterogeneity for the control and 
combination treatment groups compared with higher heterogeneity for the single agent treatment 
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groups. (B) Individual Gaussian curves were plotted and thresholds between the means of the 
Gaussian curves were color coded to inform spatial mapping. The total area under the curves is 
equal across treatment groups. Spatial mapping provides relative locations of cell 
subpopulations.  
 
6.5 Discussion 
This study characterizes head and neck cancer organoids metabolically and in response to 
drugs. This approach is advantageous because it utilizes a physiologically-relevant model 
combined with sensitive metabolic measurements of treatment response. Organoids are 
generated from tumor tissue and grow in a three-dimensional matrix, which provides a more 
appropriate model than cell lines grown as monolayers on plastic [124]. Optical metabolic 
imaging measures early therapeutic effects and characterizes cellular heterogeneity, which is 
crucial for identifying resistant cells that cause patient failure. Overall, this technique can address 
a need for high-throughput screens of treatment efficacy for anti-cancer drugs to facilitate drug 
discovery.  
High quality primary tissue facilitates organoid growth. In particular, generating 
organoids immediately after tissue excision preserves tissue viability. Successful organoids grow 
from tissue that consists of dense tumor cells with a high proliferation rate and low apoptosis rate 
(Figure 6.1). Histological analysis indicates that the primary tissue comprises ~97% tumor 
characterized by proliferative, epithelial cells and ~3% stroma characterized by fibroblasts, 
capillaries, immune cells, and collagen. Fibroblasts exhibit distinct elongated morphology that 
would be apparent in culture [125]. Endothelial cells and immune cells would be expected to 
have short life spans and expire under organoid conditions [126]. In particular, the growth of 
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endothelial cells is promoted by shear stress [127], which is largely absent in these cultures. This 
analysis suggests that the organoids comprise epithelial cells.  
Protein-binding causes a conformational change in the molecular structure of NAD(P)H 
and FAD, which affects fluorescence quenching and the fluorescence lifetime [39]. The distinct 
fluorescence lifetime properties between in vivo tumor tissue and organoids reflect distinct 
protein-binding activity, including different rates that these molecules are being used in cell 
signaling pathways and binding to different proteins (Figure 6.2). These differences could result 
from discrete microenvironment conditions, including nutrient availability and oxygenation 
between in vivo tumors and in vitro cultures. This characterization highlights the utility of 
organoids as a complementary tool to in vivo imaging by enabling rapid comparisons of 
metabolic states between treated and control organoids generated from the same tissue.  
Cell subpopulations with distinct metabolic phenotypes are present in the control 
organoids (Figure 6.3). Organoids contain cells with high levels of NAD(P)H intensity and cells 
with low levels of NAD(P)H intensity (p<0.05). Low-NAD(P)H cells exhibit a lower redox ratio 
than high-NAD(P)H cells (p<0.05), reflecting distinct metabolic characteristics. Previous studies 
have shown that a decrease in redox ratio corresponds to a decrease in cell proliferation [96], 
thus these two subpopulations of cells may have varied drug response. Additionally, these 
subpopulations exhibit different FAD fluorescence lifetimes and contributions from free FAD 
(Figure B.2, p<0.05), indicating different levels of protein-binding between these cell 
subpopulations. The lack of a tumor stroma in the organoids could enable these separate 
subpopulations of cells  to grow [128].  
Traditional measures of therapeutic response characterize each treatment group. 
Immunohistochemistry shows minimal treatment effects 2 days after treatment and measures 
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treatment response after 2 weeks of treatment (Figure 6.4). Cetuximab has been shown to induce 
autophagy instead of apoptosis [104]. Overall, these results indicate that the endpoints of cell 
proliferation and cell death require multiple courses of treatment to resolve treatment effects. 
Tumor growth curves show that control tumors exhibit disease progression, the single agent 
treatments both exhibit stable disease, and the combination treatment exhibits treatment response 
(Figure 6.4E). These results reflect the synergistic effect of cetuximab and cisplatin, because 
cetuximab enhances chemotherapy-induced cell death by inhibiting DNA repair mechanisms 
[18]. These results agree with clinical studies of patients administered cetuximab, cisplatin, or 
their combination [102][103][105]. 
Representative images show the morphology and arrangement of tumor cells in organoids 
after 1 day of treatment as well as qualitative differences in the redox ratio, NAD(P)H 
fluorescence lifetime, and FAD fluorescence lifetime across treatment groups (Figure 6.5). 
Additionally, optical metabolic imaging quantitatively demonstrates sensitivity to drug effects 
after 1 day of treatment (Figure 6.6), which is an earlier time point compared with cell death, cell 
proliferation, and tumor volume (Figure 6.4). Cetuximab treatment causes an increase in the 
redox ratio, which is consistent with decreased efficacy of cetuximab as a monotherapy 
[118][96]. Cisplatin treatment causes a decrease in the redox ratio, which is consistent with drug 
responsiveness in previous in vitro and in vivo studies [96][123]. Combination treatment causes a 
decrease in the redox ratio, which is previously unreported. Taken together these results suggest 
that a decrease in the redox ratio indicates treatment response compared with an increase or no 
change in redox ratio for less effective treatments.  
The organoids NAD(P)H fluorescence lifetime (τm) decreases with cetuximab, cisplatin, 
and combination treatments (Figure 6.6B, p<0.05), which is consistent with previous in vivo 
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results [123]. The organoids FAD fluorescence lifetime (τm) increases with cetuximab, cisplatin, 
and combination treatments (Figure 6.6C, p<0.05). This shows the opposite trend from previous 
in vivo results and reflects the difference in microenvironments between in vivo and in vitro 
conditions, including access to oxygen and nutrients, vascularization, stromal structure, and drug 
delivery. Overall, these results indicate that organoids combined with optical metabolic imaging 
provides a unique in vitro, three-dimensional model that harnesses intrinsic contrast for 
measuring early, sensitive drug effects on a single-cell level. 
Tumor heterogeneity describes multiple cell subpopulations that can respond to therapies 
with different sensitivities, and cells that are resistant to treatment can enable patient relapse. In 
particular, Gaussian fitting of cellular data can characterize cellular heterogeneity, and a 
heterogeneity index, H, can incorporate the number of subpopulations, evenness of 
subpopulations, and relative distance between subpopulations to quantify cellular heterogeneity 
[98][123]. Based on the heterogeneity index, organoids treated with the single agents 
demonstrate a higher degree of heterogeneity compared with organoids in the control and 
combination treatment groups (Figure 6.7A). As seen in the tumor growth curves (Figure 6.4E), 
combination treatment has an additive effect compared with single agent treatments and creates a 
uniform response in organoids based on the heterogeneity index (Figure 6.7A). Furthermore, 
spatial mapping provides insight into the relative locations of cell subpopulations, particularly 
for visualization of grouped versus scattered subpopulations. Representative images indicate that 
cell subpopulations are scattered across and within organoids. Ultimately, characterization of 
cellular heterogeneity provides a powerful tool for testing drugs and drug combinations.  
Head and neck cancer patients suffer from severe toxicities, serious morbidities, and 
mortalities, and these challenges can be addressed through improved therapies. In particular, 
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streamlining the complex process of drug development could make a beneficial impact by 
efficiently identifying the most effective and least toxic drugs for development. This would 
reduce the time and resources spent on drugs that ultimately fail in patients and increase the 
success rate of clinical trials. A high-throughput drug screen based on cell metabolism and single 
cell analysis can address this need. Organoids combine the in vitro nature of cell monolayers 
with a more physiologically-relevant model, while optical metabolic imaging provides a platform 
for single-cell measurements of heterogeneous therapeutic response. This study establishes a 
protocol for growing head and neck cancer organoids, characterizes the organoids metabolically, 
and measures early response to antibody therapy, chemotherapy, and combination therapy. These 
results indicate that head and neck cancer organoids combined with optical metabolic imaging 
could provide a beneficial tool during drug discovery for head and neck cancer. 
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CHAPTER 7 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Summary and Conclusions 
 The goal of this work is to develop optical metabolic imaging for measuring treatment 
response in head and neck cancer, which is a prominent cause of morbidities and mortalities. 
Current treatments cure only 50-60% of head and neck cancer patients [1]. Cancer drugs and 
drug combinations are continually being developed and approved, but there is a need for 
methods to match patients with the most beneficial drugs. Additionally, patients often experience 
initial response to treatment followed by relapse. Tumor heterogeneity can impact this treatment 
resistance [54][55], but current methods to measure treatment response focus on whole-body 
imaging. Single-cell measurements of treatment response would be beneficial to identify cell 
subpopulations that are responsible for patient relapse. Furthermore, cancer exhibits altered 
cellular metabolism [7], and metabolic measurements can resolve early treatment response. 
Overall, optical metabolic imaging could provide a tool that achieves single-cell metabolic 
measurements of anti-cancer treatment response using endogenous contrast. This technique 
could be applied to monitor early drug response, optimize personalized treatment regimens, and 
facilitate drug discovery for head and neck cancer. 
 Chapter 1 of this dissertation provides the motivation for this work. Chapter 2 provides 
background material for these studies. This chapter describes relevant information about the 
anatomy and physiology of the head and neck region, as well as the prevalence, diagnosis, and 
treatment methods for head and neck cancer. Additionally, optical techniques for head and neck 
cancer are described, and two-photon microscopy and fluorescence lifetime imaging are 
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introduced. Background information about cellular metabolism and tumor heterogeneity is also 
included. 
Chapter 3 characterizes optical metabolic imaging in human cell lines for early 
assessment of treatment efficacy. The head and neck cancer cell lines SCC25 and SCC61 were 
treated with targeted therapies (cetuximab and BGT226) and chemotherapy (cisplatin) for 24 
hours, and the optical redox ratio and fluorescence lifetimes of NAD(P)H and FAD were 
quantified. These molecular-level measurements that reflect cellular metabolism have potential 
to resolve anti-cancer treatment effects sooner than current imaging modalities, including CT, 
MRI, and PET. This early measurement of treatment efficacy could accelerate drug screening 
and identify optimal treatment regimens for individual patients, thereby improving patient 
outcomes.  
Chapter 4 characterizes optical metabolic imaging for measuring response to head and 
neck cancer treatment in vivo. Feasibility of these measurements was demonstrated in a mouse 
model with head and neck cancer xenografts, and tumor heterogeneity was characterized. The 
mice were treated with chemotherapy, a targeted drug, or their combination and the fluorescence 
intensities and lifetimes of NAD(P)H and FAD were measured in vivo 48 hours after treatment. 
These studies provide support for clinical translation of optical metabolic imaging measurements 
in patients. In particular, a portion of head and neck cancer patients initially respond to treatment 
and then relapse over time. In vivo monitoring at early time-points could reduce unnecessary 
toxicities from ineffective treatments and improve the quality of life for head and neck cancer 
patients. 
Chapter 5 translates optical metabolic imaging to human head and neck cancer tissue. 
Metabolic and structural measurements were acquired using the fluorescence lifetimes of 
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NAD(P)H and FAD as well as second harmonic generation (SHG) imaging. These methods 
probe the cancer cells and extracellular matrix, which are both components involved in treatment 
response. These measurements were characterized in patient tissue across multiple anatomical 
sites and cell types. This study indicates that optical metabolic imaging could provide a 
complementary microscopy method to conventional histology and influence treatment strategies 
for head and neck cancer patients. 
Chapter 6 applies optical metabolic imaging to an organoid model of head and neck 
cancer. The optical redox ratio and fluorescence lifetimes of NAD(P)H and FAD were applied to 
characterize head and neck cancer organoids alone and after treatment with a chemotherapy, an 
antibody therapy, or their combination. Additionally, cellular heterogeneity of the organoids was 
analyzed. The organoid model serves as a more physiologically relevant in vitro platform 
compared with cell monolayers. Organoids more closely mimic in vivo conditions because they 
grow within a three-dimensional microenvironment that includes tumor-like gradients of oxygen, 
glucose, and pH [129]. Since a portion of HNSCC patients do not respond to treatments, 
prediction of effective treatments on an individual level could enable improved treatment 
outcomes. Patient tissue could be grown in organoids, incubated with several drugs and drug 
combinations, and measured with optical metabolic imaging to predict optimal treatment 
regimens. Additionally, optical metabolic imaging applied to organoids could be developed into 
a high-throughput screen to streamline drug discovery for head and neck cancer. 
Improved measurement of treatment response in head and neck cancer has potential to 
optimize treatment regimens, reduce unnecessary morbidities and toxicities, and improve patient 
outcomes. Optical metabolic imaging harnesses intrinsic contrast to resolve early, single-cell 
response to anti-cancer treatment. In this dissertation, optical metabolic imaging has been applied 
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to head and neck cancer for in vitro cell lines, in vivo preclinical measurements, ex vivo human 
tissue, and three-dimensional organoids. Ultimately, this technique could optimize treatment 
planning and drug discovery for head and neck cancer. 
 
6.2 Future Directions 
Design a clinical system for head and neck cancer patients  
Optical metabolic imaging is well-suited to head and neck cancer because of easy access to the 
site with endoscopes and fiber-optic probes. Chapter 4 demonstrates in vivo preclinical 
measurements in head and neck cancer xenografts for resolving early, cellular-level treatment 
response to therapy. Since treatment-induced changes in cellular metabolism are affected sooner 
than tumor volume, optical metabolic imaging can provide an earlier readout of response 
compared with current methods, like CT, MRI, and PET. Measuring the autofluorescence 
intensities and lifetimes of NAD(P)H and FAD in patients could resolve response at early time-
points after treatment onset, enabling the reduction of unnecessary toxicities and costs from 
ineffective treatments.  
 
Measure treatment-induced metabolic changes in head and neck cancer over a timecourse  
Optical metabolic imaging is well-suited for measurements over time because it is non-
destructive and can be applied for intact live samples. Chapter 4 applies optical metabolic 
imaging to head and neck cancer in vivo 48 hours after treatment with a chemotherapy, an 
antibody therapy, and their combination. Chapter 6 applies optical metabolic imaging in head 
and neck cancer organoids 24 hours after treatment with a chemotherapy, an antibody therapy, 
101 
 
and their combination. Timecourse measurements could provide insight about dynamic drug 
response, treatment-inducted shifts in cellular heterogeneity, and resistance to therapy.  
 
Characterize head and neck cancer patient tissue ex vivo  
Chapter 5 provides a preliminary study applying optical metabolic imaging and second harmonic 
generation (SHG) imaging to ex vivo human patient tissues. These tissues represent a variety of 
anatomical sites and cell types across several patients. Expanding this study by increasing the 
sample size for each anatomical site could provide additional insight into the variability that 
would be expected during clinical application of this technique. Additionally, this type of study 
would enable the characterization of NAD(P)H and FAD autofluorescence lifetime and SHG 
signals in primary human head and neck cancer tissue. 
 
Characterize cellular subpopulations based on optical metabolic imaging  
Cellular heterogeneity impacts treatment response in cancer patients because resistant cells can 
drive relapse. Optical metabolic imaging can be applied to identify cell subpopulations present 
intrinsically and after drug treatment. Chapter 4 characterizes cellular heterogeneity in head and 
neck cancer in vivo, and Chapter 6 characterizes cellular heterogeneity in head and neck cancer 
organoids. A better biological understanding of these subpopulations could be valuable for 
targeting treatment-resistant cells. Studies could be applied to correlate optical metabolic 
imaging parameters for cell subpopulations with complementary metabolic or protein expression 
measurements. Additionally, Appendix C introduces flow cytometry based on cell 
autofluorescence for sorting a heterogeneous solution of cells. This approach could be applied 
for cells from primary tumors. The sorted subpopulations of cells could be used during the 
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testing of potential drugs or for planning effective treatment regimens for individual cancer 
patients. 
 
Optimize an organoid drug screen for patient-derived head and neck cancer tissue 
Optical metabolic imaging in organoids can provide a predictive screen of potential drugs for 
informed, individualized treatment planning. Chapter 6 demonstrates optical metabolic imaging 
for head and neck cancer organoids grown from xenografts. Optimizing organoid generation 
methods and culture conditions could enable organoid growth from primary human tissue. This 
type of platform could enable patient-derived organoids to be tested with several drugs and drug 
combinations to predict treatment response before therapy is administered to the patient, which 
could improve patient outcomes. 
 
Develop automated image acquisition for high-throughput studies 
Drug development takes at least 10 years and more than $1 billion [115][116]. An organoid drug 
screen combined with optical metabolic imaging could provide a platform for rapid testing 
during drug discovery and identifying promising drug candidates. Chapter 6 applies optical 
metabolic imaging for head and neck cancer organoids after 24 hours of treatment with a 
chemotherapy, antibody therapy, and their combination. However, methods for acquiring and 
analyzing optical metabolic imaging data could be improved. In particular, automated image 
acquisition and data analysis could enable high-throughput screens to test an array of 
experimental drugs and their combinations. Additionally, three-dimensional image stacks could 
sample the entire organoid volume. Overall, this method could streamline drug discovery for 
head and neck cancer. 
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Develop the biological understanding of NAD(P)H and FAD fluorescence lifetime 
The fluorescence lifetimes of NAD(P)H and FAD are still considered investigational 
measurements. A change in lifetime is usually interpreted as a change in microenvironment, 
particularly protein-binding. Chapter 3 correlates the fluorescence lifetimes of NAD(P)H and 
FAD with rates of cell proliferation and lactate production normalized by glucose consumption 
in head and neck cancer cell lines after treatment. Additional studies can explore the biological 
understanding of these fluorescence lifetime measurements, including how they change based on 
metabolic pathway preferences. 
 
6.3 Contribution to the Field and Broader Impact 
Contribution to Biophotonics 
This work demonstrates novel characterizations of NAD(P)H and FAD autofluorescence 
intensities and lifetimes in head and neck cancer. Cyanide perturbation in the nonmalignant oral 
cavity cell line OKF6 verifies NAD(P)H and FAD autofluorescence by the optical redox ratio 
and NAD(P)H and FAD fluorescence lifetimes. These shifts match published results in the 
nonmalignant MCF10A cell line from the breast [52], but these results are previously unreported 
in cells from the oral cavity. Additionally, these studies represent the first reports of the effect of 
cetuximab on the optical redox ratio. No other literature has reported the effects of chemotherapy 
in vivo on the optical redox ratio and fluorescence lifetimes of NAD(P)H and FAD. Applying the 
viSNE dimensionality reduction technique to optical metabolic imaging is a novel approach to 
visualize cellular heterogeneity based on these parameters. These studies work toward 
interpreting the fluorescence lifetimes of NAD(P)H and FAD by comparing these measurements 
with gold standard measures of treatment response, including cell death and cell proliferation, 
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and glucose metabolism. This work also compares optical metabolic imaging parameters across 
head and neck cancer models, particularly between in vivo xenografts and organoids. Overall, 
this work strengthens the foundation of applying optical metabolic imaging to resolve treatment 
response in head and neck cancer. 
 
Contribution to Head and Neck Cancer  
This work presents the first reports of measurements of endogenous fluorescence in response 
to treatment in head and neck cancer. Single-cell measurements of cell metabolism are applied to 
resolve response to drug treatment, and these studies apply novel methods for characterizing 
tumor heterogeneity. A quantitative heterogeneity index is developed and applied to head and 
neck cancer tumors and organoids. This index is advantageous because there is no standard 
metric for quantifying tumor heterogeneity. Organoids combined with optical metabolic imaging, 
as presented in this work, could provide a novel assay for high-throughput metabolic 
measurements during drug discovery for head and neck cancer therapies. 
 
Potential Impact 
About half a million new cases of head and neck cancer are diagnosed each year. Only 
50-60% of those patients will be cured by therapy [3], while the rest will show inherent 
resistance to therapy or develop resistance to therapy. Optical metabolic imaging harnesses 
intrinsic contrast of autofluorecence from cofactors that are sensitive to metabolic changes due to 
treatment. These studies characterize the optical metabolic imaging parameters in response to 
head and neck cancer treatment in human cell lines compared with gold standard measures of 
cellular metabolism and therapeutic response. Additionally in vivo studies demonstrate feasibility 
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for resolving response earlier than current methods based on tumor volume, and this approach 
can provide a basis for clinical translation of this technique for early monitoring of drug response 
in vivo. The sub-cellular resolution achieved by this technique could enable the identification of 
cellular sub-populations in response to treatment. Furthermore, translation of optical metabolic 
imaging to human patient tissues characterizes heterogeneity across tissue and cell types. In 
parallel, in vitro organoid studies develop a platform for testing drugs and drug combinations, an 
approach that could enable prediction of optimal therapy for individual patients before treatment 
is administered. Overall, optical metabolic imaging of head and neck cancer shows potential to 
impact personalized medicine and drug discovery for head and neck cancer. In particular, a 
sensitive measure of early treatment response could allow intervention during ineffective 
treatments. Clinical translation of an optical system to measure endogenous fluorescence is 
feasible because head and neck cancer sites are accessible with fiber optic probes. Additionally, 
high-throughput, physiologically-relevant platforms combined with optical metabolic imaging 
could facilitate drug discovery and predict optimal therapies to improve patient outcomes, 
minimize unnecessary toxicities, and reduce costs from ineffective therapies for head and neck 
cancer patients.  
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APPENDIX A 
SUPPLEMENTARY MATERIAL FOR CHAPTER 4 
 
 
 
Figure A.1. The short fluorescence lifetime (τ1), long fluorescence lifetime (τ2), and contribution 
of free conformations of NAD(P)H and FAD 2 days after treatment. (A, B, D, E) The short and 
long lifetime components of NAD(P)H and FAD decrease with cetuximab and cisplatin 
treatment. (C, F) The contribution of free NAD(P)H increases and the contribution of free FAD 
decreases with cetuximab and cisplatin treatment. *p<0.05, compared with control 
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Figure A.2. The heterogeneity index was calculated for the short fluorescence lifetime (τ1), long 
fluorescence lifetime (τ2), and contribution of free conformations of NAD(P)H and FAD. For 
NAD(P)H τ1, NAD(P)H τ2, % free NAD(P)H, FAD τ1, FAD τ2, and % free FAD the control 
group exhibits decreased heterogeneity indices compared with the cetuximab and cisplatin 
treatment groups.  
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Figure A.3. ViSNE heat maps. Heat maps of (A) the redox ratio, (B) the long fluorescence 
lifetime component of NAD(P)H, (C) the contribution of free conformation of NAD(P)H , (D) 
the long fluorescence lifetime component of NAD(P)H, and (E) the contribution of free 
conformation of FAD over the 2-dimensional viSNE axes. 
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Figure A.4. Heterogeneity analysis for FaDu cell monolayers in vitro for cetuximab and cisplatin 
treatments compared with control. (A) The heterogeneity index based on the redox ratio is 
increased for cetuximab and cisplatin treatments compared with control. (B) ViSNE analysis 
shows overlap for control, cetuximab, and cisplatin groups as well as non-overlapping 
subpopulations for the cetuximab and cisplatin groups. 
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APPENDIX B 
SUPPLEMENTARY MATERIAL FOR CHAPTER 6 
 
 
 
Figure B.1. Untreated organoids and in vivo tumor tissue exhibit distinct NAD(P)H and FAD 
fluorescence lifetime components. Organoids have lower contributions of the short lifetime 
component (α1), higher values of the short fluorescence lifetime (τ1), and higher values of the 
long fluorescence lifetime (τ2). *p<0.05, t-test, n~100-300 cells per group 
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Figure B.2. NAD(P)H and FAD fluorescence lifetime components characterize cells in untreated 
organoids with low levels of NAD(P)H fluorescence compared with cells with high levels of 
NAD(P)H intensity. NAD(P)H fluorescence lifetime components are similar, whereas low 
NAD(P)H cells have lower contribution of FAD short lifetime component (α1). 
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Figure B.3. NAD(P)H and FAD fluorescence lifetime components were quantified in organoids 
after 1 day of treatment. For NAD(P)H, cetuximab treatment causes an increase in the short 
lifetime component (α1), whereas cisplatin and combination treatment cause a decrease in the 
short lifetime component. Cetuximab, cisplatin, and combination treatments cause a decrease in 
the short (τ1) and long (τ2) fluorescence lifetimes. For FAD, cetuximab, cisplatin, and 
combination treatments cause a decrease in the contribution of the short lifetime (α1) and an 
increase in the short (τ1) and long (τ2) fluorescence lifetimes. 
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APPENDIX C 
AUTOFLUORESCENCE FLOW SORTING OF BREAST CANCER CELL 
METABOLISM 
 
C.1 Abstract 
Clinical cancer treatment aims to target all cell subpopulations within a tumor. 
Autofluorescence microscopy of the metabolic cofactors NAD(P)H and FAD has shown 
sensitivity to anti-cancer treatment response. Alternatively, flow cytometry is attractive for high 
throughput analysis and flow sorting. This study characterizes cellular autofluorescence in three 
flow cytometry channels and applies cellular autofluorescence to sort a heterogeneous mixture of 
breast cancer cells into subpopulations enriched for each phenotype. Sorted cells were grown in 
culture and sorting was validated by morphology, autofluorescence microscopy, and receptor 
expression. Ultimately, this method could be applied to improve drug development and 
personalized treatment planning.  
 
C.2 Introduction 
Tumor heterogeneity can impact treatment response for cancer patients. Tumors can 
contain multiple subpopulations of cells with distinct phenotypes and sensitivities to drugs, and 
cells that are resistant to treatment can cause patient relapse [54]. The goal in clinical cancer 
treatment is to administer drugs that target all cell subpopulations within a tumor, leading to 
progression-free survival. Therefore, single-cell analysis techniques have become powerful tools 
for characterizing tumor heterogeneity and developing strategies to eliminate all treatment-
resistant cells in a tumor.  
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Subpopulations of tumor cells can be defined by responsiveness or resistance to anti-
cancer treatment. Responsive cells undergo cell death or senescence after treatment, whereas 
resistant cells continue to proliferate after treatment. Since cancer cells often exhibit altered 
cellular metabolism, particularly increased aerobic glycolysis (Warburg effect), and many drugs 
target metabolic pathways, cellular metabolism can be a marker for drug sensitivity [130]. 
Metabolic signaling pathways involve the cofactors NAD(P)H and FAD, and these molecules 
naturally exhibit autofluorescence. Previous studies have shown that breast cancer cells that are 
responsive to treatment exhibit a decreased ratio of NAD(P)H fluorescence to FAD fluorescence, 
termed the optical redox ratio, compared with cells that are resistant to treatment [52]. The redox 
ratio has also been used to distinguish subtypes of breast cancer cells with different receptor 
statuses, including human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor 
(ER)-positive, and triple negative cells. Specifically, the triple negative breast cancer cell line 
MDA-MB-231 has been shown to exhibit a lower optical redox ratio than the HER2-positive 
breast cancer cell line SKBr3 [52]. To mimic cellular heterogeneity, SKBr3 cells and MDA-MB-
231 cells have been mixed in culture, and distinct subpopulations of each cell line have been 
identified using autofluorescence microscopy of NAD(P)H and FAD [98]. Therefore, single cell 
measurement techniques of cellular autofluorescence are beneficial to characterize heterogeneity 
across breast cancer subtypes. 
Single cell techniques to measure fluorescence include microscopy and flow cytometry, 
and each of these has unique advantages. Microscopy provides higher resolution (sub-cellular) 
and requires a longer dwell time (ms), whereas flow cytometry provides lower resolution 
(cellular) and requires a shorter dwell time (µs). Microscopy measures smaller sample sizes 
(hundreds of cells) compared with flow cytometry (thousands of cells). Additionally, microscopy 
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measures adherent cells and can provide information about spatial relationships between cells, 
whereas flow cytometry measures cells in suspension and can sort cells to enrich cell 
subpopulations based on a target fluorophore. Overall, microscopy provides high signal to noise 
whereas flow cytometry provides high throughput and cell sorting. Flow cytometry is well-suited 
for characterizing cellular heterogeneity because sorting cancer cells by metabolic fluorophores 
could isolate subpopulations that could then be grown in vitro and used for further analysis. In 
particular, cell subpopulations could be tested for sensitivity to anti-cancer therapies to determine 
personalized treatment strategies as well as to develop new therapies for isolated resistant 
subpopulations.  
Current methods for flow sorting tumor cell subpopulations are based on fluorescent 
staining for specific molecular markers, and some studies have identified markers for treatment 
resistance. In particular, CD44+ cells have been shown to be tumorigenic and resistant to 
chemotherapy in breast cancer, head and neck cancer, and pancreatic cancer 
[131][132][133][134]. CD24 has also been shown to be a marker for tumorigenic potential in 
breast cancer and pancreatic cancer. Additionally, CD133+ cells have been shown to be 
tumorigenic and resistant to chemotherapy in pancreatic cancer [135]. However, there are 
drawbacks to fluorophore staining for flow cytometry. In particular, labeling efficiency can 
affect the signal intensity from fluorophore staining, thus confounding the interpretation of 
“positive” and “negative” stained cells. Therefore, autofluorescence measurements can be 
beneficial by eliminating the need for dyes or stains. Additionally, staining for specific markers 
could miss cells that maintain treatment resistance yet circumvent the labeled pathway. 
Therefore, autofluorescence of NAD(P)H might be an advantageous marker to sort cells based 
on overall cell metabolism.  
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Previous studies have also applied flow cytometry based on intrinsic contrast. In addition 
to measuring cell fluorescence, flow cytometry measures scattering properties of the cells, 
including forward scattering measurements (FSC), which reflect cell size. These scattering 
properties have been used to distinguish cells of different sizes and types, including isolating 
neutrophils from leukocytes [136]. Additionally, NAD(P)H and FAD autofluorescence flow 
cytometry has been shown to measure response to increasing concentrations of glucose in rat b-
cells, INS-1 cells, and rat islet cells [137][138]. Since flow cytometry measures fluorescence 
intensities per cell, cell size could affect autofluorescence measurements. For example, cells 
from the bottom ten percent of the autofluorescence intensity distribution have been shown to 
have decreased size compared with cells from the top ten percent [139]. Therefore, it is 
important to compare autofluorescence intensities from cells with similar sizes and FSC values. 
This study applies flow cytometry for autofluorescence measurements of cell metabolism 
in breast cancer. Three flow cytometry channels were characterized for cellular autofluorescence 
in a nonmalignant breast cancer cell line after electron transport chain inhibition as well as 
between two breast cancer cell lines that exhibit either overexpression of HER2 or triple negative 
status.  Additionally, a heterogeneous sample of these two cell lines was sorted based on cell 
autofluorescence, and the sorted subpopulations, which were enriched for each cell line, were 
grown in culture. Flow sorting was validated by cell morphology, autofluorescence microscopy, 
and staining for HER2 receptor expression. These results indicate that flow sorting by cell 
autofluorescence can separate phenotypic subpopulations of cells. Ultimately, this achievement 
could be applied to cells from patient tissue to enable more specific testing of tumor 
heterogeneity in cell subpopulations sorted by treatment response, ultimately driving improved 
treatment regimens for cancer patients.  
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C.3 Methods 
Cell Culture 
MCF10A cells were grown in Mammary Epithelial Cell Growth Medium (MEBM) 
supplemented with 1µg/ml insulin, 10ng/ml epidermal growth factor (EGF), and 1µg/ml 
hydrocortisone. MDA-MB-231 and SKBr3 cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin:streptomycin. For flow cytometry experiments, cells were trypsinized and prepared as 
10
6
 cells in 1ml phosphate buffered saline (PBS) with 5% FBS. For the cyanide experiment, 
cyanide (4mM NaCN, Sigma) was added to the cell solution for 5 minutes. For flow sorting 
experiments, cells were prepared as 7*10
6
 cells in 1ml PBS with 5% FBS. Cells recovered from 
flow sorting were plated and grown on 35-mm glass-bottomed dishes (MatTek Corp.) for 1 
week. 
 
Flow Cytometry and Flow Sorting 
The BD LSRII instrument was used for flow cytometry analysis experiments, and 3 fluorescence 
channels were analyzed. The DAPI channel used an excitation wavelength of 350nm and an 
emission filter of 450/50nm. The Alexa Fluor 405 channel used an excitation wavelength of 
405nm and an emission filter of 450/50nm. The Alexa Fluor 488 channel used an excitation 
wavelength of 488nm and an emission filter of 505nm longpass. 10,000 cells were analyzed for 
each group. The BD FACSAria III instrument was used for flow sorting experiments, and 1 
fluorescence channel was analyzed. The Alexa Fluor 405 channel used an excitation wavelength 
of 405nm and an emission filter of 450/50nm. Initial analysis was done on separate samples of 
MDA-MB-231 and SKBr3. Then the two cell lines were mixed at a ratio of 50% each, and the 
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heterogeneous solution was analyzed and sorted. For each cell line 3-5*10
5
 cells were recovered 
after sorting. Cells were also analyzed post-sort. Graphs were made in Cytobank 
(www.cytobank.org). Experiments were repeated in triplicate on separate days, and results were 
consistent across experiments.  
 
Microscopy Validation  
Sorted cells were grown in culture for 1 week and imaged with brightfield and fluorescence 
microscopy. For brightfield microscopy, images were acquired using an inverted microscope 
(EVOS, Fisher Scientific) and 4X objective. For fluorescence microscopy, images were acquired 
using an inverted two-photon microscope (Bruker, and TiE, Nikon) and 40X oil-immersion 
objective (1.3 NA). Incident light was provided with a titanium:sapphire laser (Coherent, Inc.). A 
GaAsP photomultiplier tube (H7422P-40, Hamamatsu) was used to collect fluorescent photons. 
NAD(P)H was measured using an excitation wavelength of 750nm and an emission filter of 
440/80nm. FAD was measured using an excitation wavelength of 890nm and an emission filter 
of 550/100nm. NAD(P)H and FAD were measured from the same fields of view. Each image 
averaged 4 frames, and 9 fields of view were imaged per group. Microscopy images were 
analyzed on a per-cell basis using a CellProfiler routine described previously [97]. Briefly, the 
optical redox ratio was calculated by dividing the image of NAD(P)H by the image of FAD for 
the same field of view. NAD(P)H images were thresholded to identify cell cytoplasms. 
NAD(P)H, FAD, and redox ratio images were quantified per cell.  
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HER2 Expression Validation 
A fluorescently labeled anti-HER2 antibody, HER2Sense (5µM, PerkinElmer), was used to 
validate flow sorting. HER2Sense exhibits optimal excitation at 643nm and emission at 661nm. 
This fluorescence was measured with the Alexa 647 channel, which has an excitation wavelength 
at 633nm and a collection filter of 660/20nm. Cells were stained with HER2Sense for 30 minutes 
and washed with PBS. MDA-MB-231 and SKBr3 cells were characterized separately, mixed to 
form a heterogeneous solution, and sorted based on autofluorescence in the Alexa Fluor 405 
channel. Next, sorted cells were characterized for autofluorescence in the Alexa Fluor 405 
channel and for HER2 expression in the Alexa 647 channel. Sorted cells were grown for 1 week 
in culture, stained with HER2Sense for 30 minutes, washed with PBS, and imaged with an 
inverted confocal microscope (Meta, Zeiss) and 40X oil-immersion objective using the cy5 
channel (maximal excitation and emission wavelengths of 647nm and 665nm). Pure, unstained 
MDA-MB-231 and SKBr3 cells served as negative controls for flow cytometry and confocal 
microscopy experiments. 
 
Statistical Analysis 
Bar graphs are shown as mean ± standard error. Statistical testing was performed using two-
tailed t-tests with an α of 0.05 indicating statistical significance.  
 
C.4 Results 
Autofluorescence signals were measured in nonmalignant MCF10A cells after treatment 
with cyanide, which is an established metabolic perturbation (Figure C.1A). Cyanide inhibits the 
electron transport chain and prevents the conversion of NADH to NAD+, thereby causing an 
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accumulation of NADH [71]. NAD(P)H has an excitation maximum at 351nm and an emission 
maximum at 440nm [40]. These spectral properties align with the DAPI flow cytometry channel, 
which excites at 350nm and collects emission between 450/50nm. The Alexa Fluor 405 flow 
cytometry channel, which excites at 405nm and collects emission between 450/50nm, has also 
been used to measure NAD(P)H [140]. FAD has an excitation maximum at 450nm and an 
emission maximum at 535nm [40]. These spectral properties align with the Alexa Fluor 488 flow 
cytometry channel, which excites at 488nm and collects emission longer than 505nm. Flow 
cytometry data shows a slight increase in the DAPI channel. This is a small change and is 
consistent across three separate replicate experiments on different days. The Alexa Fluor 405 
channel shows no change, indicating that this channel is less optimized for NAD(P)H 
measurements. The Alexa Fluor 488 channel shows a slight decrease. Additionally, the FSC 
measurements indicate that cell size is not affected by the cyanide treatment (Figure C.1B). 
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Figure C.1. Cyanide characterization. (A) Treatment with cyanide causes an increase in the 
DAPI channel, no change in the Alexa Fluor 405 channel, and a decrease in the Alexa Fluor 488 
channel. (B) Treatment with cyanide has no effect on FSC measurements, which reflect cell size. 
 
The triple negative breast cancer cell line MDA-MB-231 and the HER2-positive breast 
cancer cell line SKBr3 were characterized in the DAPI, Alexa Fluor 405, and Alexa Fluor 488 
channels (Figure C.2A). The SKBr3 cells exhibit an increased fluorescence signal in the DAPI 
and Alexa Fluor 405 channels, which correspond to NAD(P)H, compared with MDA-MB-231 
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cells. SKBr3 cells show a slight increase in the Alexa Fluor 488 channel compared with MDA-
MB-231 cells. The FSC measurements show similar cell sizes between the cell lines (Figure 
C.2B). 
 
 
Figure C.2. Cell line characterization. (A) MDA-MB-231 cells exhibit lower fluorescence 
intensity in the DAPI, Alexa Fluor 405, and Alexa Fluor 488 channels compared with SKBr3 
cells. (B) MDA-MB-231 and SKBr3 cells exhibit similar FSC measurements, which reflect cell 
size. 
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The distinct fluorescence intensities of MDA-MB-231 and SKBr3 cells in the Alexa 
Fluor 405 channel justifies applying this channel for sorting a heterogeneous sample of these two 
cell lines. Pure samples of MDA-MB-231 and SKBr3 cells show separate peaks for each cell line 
(Figure C.3A, blue, orange). The cell lines were mixed to create a heterogeneous sample, and 
this sample exhibits two distinct peaks that align with the peaks of each pure cell line (Figure 
C.3A, green). The sample was sorted based on fluorescence intensity in the Alexa Fluor 405 
channel. Similarly, the sorted cell subpopulations exhibit peaks that align with the peaks of each 
pure cell line (Figure C.3A, red, purple). Error in the sorting was less than five percent based on 
post-sort analysis. FSC measurements indicate similar cell sizes between the MDA-MB-231 
cells, SKBr3 cells, mixture of the two cell lines, and sorted SKBr3 cells (Figure C.3B). The 
sorted MDA-MB-231 cells exhibit slightly lower FSC values. 
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Figure C.3. Flow sorting. (A) MDA-MB-231 cells and SKBr3 cells measured separately exhibit 
distinct fluorescence intensities in the Alexa Fluor 405 channel. A mixture of MDA-MB-231 and 
SKBr3 cells exhibit two peaks, representing each cell type. Flow sorting the mixture separates 
the two populations of cell types. (B) FSC measurements show that MDA-MB-231, SKBr3, the 
mixture, and the sorted SKBr3 cells exhibit similar cell sizes. Sorted MDA-MB-231 cells exhibit 
a slightly decreased FSC measurement. 
 
The sorted cell subpopulations were grown in culture for one week and validated with 
brightfield microscopy to visualize cell morphology (Figure C.4). Images show pure MDA-MB-
231 cells exhibit an elongated morphology, whereas pure SKBr3 cells show a round and grouped 
morphology. Furthermore, the sorted cells from each subpopulation exhibit morphologies that 
align with the pure cell subpopulations. 
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Figure C.4. Brightfield microscopy validates cell sorting. Images illustrate an agreement in 
morphology between pure and sorted MDA-MB-231 and SKBr3 cell lines. 
 
Additionally, fluorescence microscopy was applied to validate cell sorting (Figure C.5). 
Sorted cells were grown in culture for a week and autofluorescence images of NAD(P)H and 
FAD were acquired. Representative images show the expected cell morphology for each cell line 
(Figure C.5A). The microscopy images were quantified on a cellular level to compare 
fluorescence intensities between the sorted cell subpopulations. The sorted SKBr3 cells exhibit 
higher NAD(P)H intensity (Figure C.5B), FAD intensity (Figure C.5C), and redox ratio (Figure 
C.5D) compared with MDA-MB-231 cells (p<0.05).  
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Figure C.5. Fluorescence microscopy validation of flow sorting a mixture of MDA-MB-231 and 
SKBr3 cells. (A) Representative images of NAD(P)H and FAD autofluorescence show the 
expected morphology from MDA-MB-231 and SKBr3 cells grown in culture for 1 week after 
flow sorting. (B, C) SKBr3 cells exhibit increased NAD(P)H and FAD intensities compared with 
MDA-MB-231 cells. (D) SKBr3 cells exhibit increased optical redox ratio (NAD(P)H/FAD) 
compared with MDA-MB-231 cells. n~170-200 cells. *p<0.05, t-test. mean+/- SEM 
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Fluorescence staining of HER2 expression was applied for a final validation of flow 
sorting (Figure C.6). HER2Sense labels HER2-positive cells, and excites and emits at 
wavelengths longer than NAD(P)H and FAD so it can be spectrally separated in the Alexa 647 
channel. Flow sorting based on autofluorescence in the Alexa Fluor 405 channel was repeated 
with cells stained for HER2Sense (Figure C.6A). Unstained controls exhibit minimal 
fluorescence in the Alexa 647 channel (Figure C.6B, brown, pink). Stained SKBr3 cells exhibit 
increased fluorescence signal in the Alexa 647 channel compared with stained MDA-MB-231 
cells (Figure C.6B, blue, orange). The cell lines were mixed, and the fluorescence profile of the 
mixture (Figure C.6B, green) matches the sum of the initial populations. The mixture was sorted 
based on autofluorescence in the Alexa Fluor 405 channel (Figure C.6A). After sorting, the 
Alexa 647 fluorescence for each subpopulation (Figure C.6B red, purple) matches the peaks for 
each pure cell line. FSC measurements (Figure C.6C) are similar across the samples, indicating 
similar cell sizes across the groups. Additionally, sorted cells were grown in culture for a week 
and fluorescence microscopy of HER2Sense was performed (Figure C.6D). Unstained controls 
show low background signal. As a positive control, stained SKBr3 cells show the localization of 
HER2 in the cell membrane, whereas stained MDA-MB-231 cells exhibit low signal. Similarly, 
sorted subpopulations of SKBr3 cells show the localization of HER2 in the cell membrane, 
whereas MDA-MB-231 cells exhibit low signal.  
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Figure C.6. HER2 staining validates flow sorting. (A) Autofluorescence in the Alexa Fluor 405 
channel sorts a mixture of MDA-MB-231 and SKBr3 cells. (B) Staining with a fluorescent anti-
HER2 antibody (HER2Sense) validates flow sorting. (C) FSC measurements indicate similar cell 
sizes across control and sorted groups. (D) Microscopy of sorted cells grown for 1 week shows 
the presence of HER2 in SKBr3 cell membranes compared with low, non-specific signal in 
MDA-MB-231 cells. “Stained” indicates cells were labeled with HER2Sense, whereas 
“unstained” indicates that cells were not labeled with HER2Sense. 
129 
 
C.5 Discussion 
Tumor heterogeneity describes multiple subpopulations of cells within a tumor. 
Subpopulations of cells that are resistant to treatment can cause patient relapse. Therefore, 
sorting these subpopulations could enable improved treatment regimens that target all cell 
phenotypes. The goal of this study is to apply flow cytometry and flow sorting to breast cancer 
cell metabolism based on autofluorescence. This study characterizes the effect of the metabolic 
inhibitor cyanide on three autofluorescence channels. Additionally, the autofluorescence profiles 
of MDA-MB-231 triple negative breast cancer cells and SKBr3 HER2-positive breast cancer 
cells were measured using these flow cytometry channels. A heterogeneous mixture of these two 
cell lines was sorted into subpopulations enriched for each cell line based on autofluorescence 
flow cytometry. Sorting was validated with flow cytometry, brightfield microscopy, 
autofluorescence microscopy, and HER2 staining. Overall, this technique could be applied to 
tumor cells from patient tissue by separating subpopulations of cells, testing sensitivities to anti-
cancer treatments, and planning optimal treatment schemes for individual patients.  
Autofluorescence measurements using flow cytometry channels were characterized using 
a cyanide perturbation in MCF10A cells (Figure C.1). Previous studies using confocal 
microscopy have shown that electron transport chain inhibition with cyanide causes an increase 
in NAD(P)H intensity and a decrease in FAD intensity [53], and flow cytometry results show 
similar trends. Flow cytometry resolves a slight, consistent increase in the DAPI channel, which 
aligns with NAD(P)H fluorescence, and decrease in the Alexa Fluor 488 channel, which aligns 
with FAD fluorescence. However, flow cytometry exhibits a smaller magnitude of change 
compared with confocal microscopy results. These trends in the autofluorescence flow cytometry 
channels were also consistent after treatment with 5x and 10x higher doses of cyanide (data not 
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shown). This reflects a decrease in signal to noise for flow cytometry compared with high-
resolution microscopy, due to shorter dwell times and lower spatial resolutions. As an additional 
consideration, flow cytometers are designed for use with bright fluorescent dyes and exhibit 
decreased sensitivity for the low fluorescence intensity of cellular autofluorescence. 
Furthermore, MCF10A cells are naturally adherent and could react differently to cyanide in 
suspension compared with in monolayer. Previous studies have applied the Alexa Fluor 405 
channel to measure cell autofluorescence [139]. However, cyanide treatment causes no change in 
the Alexa Fluor 405 channel. These results indicate that the DAPI channel is more optimized for 
NAD(P)H measurements compared with the Alexa Fluor 405 channel. FSC measurements show 
no change after cyanide treatment, reflecting similar cell sizes and indicating that the changes in 
fluorescence intensities are not confounded with changes in cell size. These results characterize 
the three flow cytometry channels for cell autofluorescence measurements.  
Flow cytometry measures distinct autofluorescence intensities between the triple negative 
MDA-MB-231 cell line and the HER2-positive SKBr3 cell line (Figure C.2). The DAPI and 
Alexa Fluor 405 channels exhibit increased fluorescence intensity in SKBr3 cells compared to 
MDA-MB-231 cells. This reflects increased NAD(P)H intensity and matches published redox 
ratio results  from these cell lines using confocal microscopy [52]. Although the DAPI channel 
best aligns with the spectra properties of NAD(P)H, the 350nm laser is rare in flow cytometers 
and flow sorters, whereas the 405nm laser used in the Alexa Fluor 405 channel is common. The 
FSC measurements show no difference in cell size between the cell lines, which confirms that 
changes in NAD(P)H fluorescence intensity are not an artifact of cell size. Overall, the 
separation between MDA-MB-231 and SKBr3 cells in the Alexa Fluor 405 channel indicate that 
this channel could be used to sort these cell lines. 
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Flow sorting based on the Alexa Fluor 405 channel separates a heterogeneous mixture of 
breast cancer cells into subpopulations of HER2-positive SKBr3 cells and triple negative MDA-
MB-231 cells (Figure C.3). The FSC measurements indicate a slightly smaller cell size for the 
sorted MDA-MB-231 cells. This could reflect the effect of cell size on autofluorescence intensity 
and highlights the importance of comparing autofluorescence intensity across cells with similar 
sizes. These results lay the foundation for future applications to dissociate cells from tumor 
tissue and sort subpopulations with different metabolic phenotypes, receptor statuses, and 
treatment sensitivities. Furthermore, the isolation of treatment-resistant cells could enable 
additional characterization of these cell subpopulations to identify targets for drug development 
as well as tests for sensitivity to drugs and drug combinations that aim to eliminate these resistant 
cells.  
Brightfield microscopy, fluorescence microscopy, and HER2 staining provide additional 
validations for cell sorting. Cell morphologies of sorted cells grown for one week in culture align 
with morphologies of each pure cell line (Figure C.4) and are consistent with previous 
morphological studies of these cell lines grown on glass [141]. Autofluorescence 
characterization, particularly NAD(P)H fluorescence intensity, FAD fluorescence intensity, and 
redox ratio, of sorted subpopulations enriched for each cell type agrees with published confocal 
microscopy results from SKBr3 and MDA-MB-231 cell lines (Figure C.5) [52]. HER2 staining 
further validates the sorting of a heterogeneous mixture into subpopulations of each cell line 
(Figure C.6). Previous studies have shown that SKBr3 cells stained for HER2 expression exhibit 
positive membrane signal, whereas MDA-MB-231 cells exhibit minimal signal [142]. Flow 
cytometry and confocal microscopy of HER2Sense confirm increased HER2 expression in pure 
and sorted SKBr3 cells compared with pure and sorted MDA-MB-231 cells. Overall, these 
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microscopy and staining techniques confirm the separation of a heterogeneous mixture of breast 
cancer cell lines with distinct phenotypes into subpopulations enriched for each cell type based 
on autofluorescence flow sorting. 
Tumors can contain cells with different receptor statuses, metabolic profiles, and 
responses to treatments. Cancer patients often exhibit relapse after treatment, which could be 
attributed to subpopulations of cells that are resistant to treatment. Single-cell measurements that 
reflect treatment response would allow improved treatment regimens for cancer patients. This 
study applies flow cytometry and flow sorting to nonmalignant breast cells, triple negative breast 
cancer cells, and HER2-positive breast cancer cells. These results characterize three flow 
cytometry channels for cell autofluorescence and indicate that flow cytometry based on cellular 
autofluorescence distinguishes two breast cancer cell lines with different receptor expressions. 
Furthermore, flow sorting based on cell autofluorescence separates a heterogeneous mixture into 
subpopulations enriched for each cell line. Ultimately, this technique could analyze cell 
heterogeneity from tumor tissue by sorting cell subpopulations based on metabolic profile. This 
method could be applied to preclinical studies for drug discovery, testing experimental drugs, 
and optimizing drug combinations. Furthermore, this method could be applied clinically to tissue 
from cancer patients to develop individualized treatment strategies and improve patient 
outcomes.  
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